Podcasts about mrna

The COVID hospital protocols roundtable put grieving families, doctors, and lawmakers in the same room, asking a question the country has spent years avoiding: What really happened after patients entered the hospital?Then, a group of doctors and scientists is demanding Secretary Kennedy act on mRNA technology—or risk losing their support. Dr. Robert Malone, one of the letter's signatories, joins Del for a conversation that gets right to the fault line.And as Breast Cancer Awareness Month begins, millions of women are deciding whether to schedule a mammogram this year. Integrative oncologist and breast surgeon Dr. Jennifer Simmons joins Del to talk about the growing concerns around conventional screening and whether the advice women have received for years could be contributing to the rise in breast cancer.Guests: Robert Malone, MD, MS, Jennifer Simmons, MDBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.

Florida's Attorney General has filed a major lawsuit against Pfizer and CEO Albert Bourla over alleged deceptive practices and safety concerns surrounding their COVID-19 vaccine.

Florida Attorney General James Uthmeier has officially filed a lawsuit against Pfizer and CEO Albert Bourla, alleging deceptive practices and misleading public claims regarding COVID-19 vaccine safety. We break down the details of the lawsuit, the debate surrounding federal health agencies, and the broader discussion on mRNA technology and traditional flu vaccines.

TODAY ON THE ROBERT SCOTT BELL SHOW: Jonathan Emord, Supplement Free Speech, Democratic Socialism Promises, Pharma Lobbying Surge, Trump Rejects UN Plan, Food Industry Pushback, Brian Hooker, MAHA mRNA Open Letter, Nuphar Luteum and MORE! https://robertscottbell.com/jonathan-emord-supplement-label-fight-democratic-socialism-pharma-lobbying-surge-un-pandemic-trump-rejection-food-industry-pushback-brian-hooker-mrna-open-letter-nuphar-luteum/ Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

Terrifying for passengers aboard a FlyDubai plane when the radical Muslim jihadi co-pilot stabs his Jewish captain in the cockpit and tries to fly the plane into the ground, ala Flight 93. Why does the media have to lie to protect Muslims who chant death to America? Some of America's doctors who helped elect Trump and have supported RFK's MAHA agenda say they will sit out the midterms if the administration doesn't rescind the FDAs approval of anything mRNA. The generic ballot shows a virtual toss up for the midterms - which is not the news the DNC needed to hear.  

Interview with Stephen Thomas, MD

Sign up for weekly webinars: https://imahealth.org/weekly-webinars/ign up for weekly webinars: Weekly Webinars - Independent Medical Alliance What does the data show when Moderna's mRNA flu vaccine is evaluated using absolute measures of benefit and risk?IMA President and Chief Medical Officer Dr. Joseph Varon was joined by Dr. Peter McCullough, Nicolas Hulscher, and Dr. John Catanzaro to examine their new reanalysis of FDA clinical trial data for Moderna's mFLUSIVA (mRNA-1010).They discussed:• The vaccine's reported efficacy and absolute clinical benefit• Adverse reactions and reactogenicity seen in the clinical trials• Mortality findings highlighted in the authors' reanalysis• Why the authors believe the data raise unanswered questions about the vaccine's benefit-risk profile and continued licensureThe Independent Medical Alliance (formerly FLCCC) is a healthcare nonprofit on a mission to restore trust, integrity, and the doctor-patient relationship. Get involved by clicking below:• Donate: Support IMA: Donate for Advancements in Patient Care https://imahealth.org/donate/• Follow: Connect with Us - https://imahealth.org/contact/• Weekly Webinars: - https://imahealth.org/category/weekly-webinars/• Treatment Protocols: - https://imahealth.org/treatment-protocols/• Medical Disclaimer: https://imahealth.org/about/terms-and-conditions/

About this episode:   For the first time ever, mRNA flu shots are available this respiratory virus season for adults age 50 and older, offering an opportunity to create vaccines better tailored to certain strains of the virus. Moderna's mFLUSIVA was approved by the FDA this summer and is available in some pharmacies. In this episode: Vaccine expert Anna Durbin explains how the vaccine works, discusses the current data on its safety and efficacy, and reflects on the quest for a universal flu vaccine. Guest:  Dr. Anna Durbin is a professor of International Health and the director of the Johns Hopkins Center for Immunization Research.  Host:  Stephanie Desmon, MA, is a former journalist, author, and the director of public relations and communications for the Johns Hopkins Center for Communication Programs. Show links and related content:  New mRNA Flu Vaccine Makes This Flu Season 'One to Watch'—Johns Hopkins Bloomberg School of Public Health August 5, 2026 Clinical Review - MFLUSIVA—FDA How Influenza (Flu) Vaccines Are Made—CDC How Flu Viruses Can Change: "Drift" and "Shift"—CDC The Long History of mRNA Vaccines—Johns Hopkins Bloomberg School of Public Health A Guide to Fall Vaccines for People Who Are Immunocompromised and Those Who Care For Them—Public Health On Call (September 2026) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. You can also email PublicHealthQuestion@jhu.edu to request a transcript. AI disclosure (as of September 2026): The conversations you hear on the podcast are happening between real humans, and real humans are developing and researching episodes behind the scenes. In addition to real human audio engineers, Public Health On Call uses AI production tools to assist with the removal of filler words and improve audio quality. If you have any questions about our use of AI, please reach out to PublicHealthQuestion@jhu.edu.  Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌PublicHealthPod on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

Immune tackles papers on the breadth of human B cell responses following mRNA vaccination and on the role of mitochondria and reactive oxygen species in plasma B cell maintenance. Hosts: Vincent Racaniello, Cindy Leifer, Stephanie Langel, and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server mRNA flu vaccine expands B cell breadth (Nat Immunol, 2026) Mitochondrial ROS and plasma cells (Nat Commun, 2026) Time stamps by Jolene Ramsey. Thanks! Music by Tatami. Immune logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv Information on this podcast should not be construed as medical advice.

On this week's episode of The Ultimate Assist, John Stockton and Ken Ruettgers welcome back epidemiologist Nicolas Hulscher, MPH, for a provocative conversation about childhood vaccines, vaccinated-versus-unvaccinated health outcomes, MMR, mRNA technology, cancer, myocarditis, and the future of vaccine policy in America.Nicolas returns to the show with new research and some controversial conclusions.At the center of the conversation is a retrospective analysis of medical records from children within the Henry Ford Health system. Hulscher argues that the data raise serious questions about differences in chronic-disease diagnoses between vaccinated and unvaccinated children and says the findings warrant much greater scrutiny of the childhood vaccine schedule. John and Ken challenge Nicolas on what those findings mean for parents. Are the apparent differences actually caused by vaccination? What are the tradeoffs of foregoing vaccines against diseases such as measles, mumps and polio? And has enough high-quality research been conducted to give parents the answers they deserve? Hulscher argues that current evidence warrants far greater caution, while acknowledging at points that some disease-specific associations cannot yet be established with certainty. The conversation gets even more controversial when Nicolas discusses what he calls “turbo cancer.” He describes research he believes points toward unusually aggressive cancers following COVID-19 vaccination and lays out proposed biological mechanisms involving mRNA technology and spike-protein production. These interpretations remain contested, but Hulscher argues that the signals deserve much more investigation rather than dismissal. John, Ken and Nicolas also explore:Vaccinated versus unvaccinated health outcomesWhy Nicolas is particularly concerned about the MMR vaccineWhether the childhood vaccine schedule has been adequately studied as a wholeMyocarditis and neurological adverse eventsThe debate surrounding “turbo cancers”How long vaccine-derived material may persist in the bodyWhether mRNA technology should continue to be developedWhat Nicolas believes regulators are getting wrongWhy he says he's more concerned today than he was during his first appearanceToward the end of the episode, Nicolas discusses ongoing research into spike-protein reduction and proposed studies involving repurposed drugs in cancer patients, before explaining why he believes emerging biotechnology deserves far greater public scrutiny. In rapid fire, Nicolas doesn't hedge when John asks which vaccine is most misunderstood:“All of them.”And when asked whether mRNA technology should be studied harder or abandoned, his answer is equally unequivocal:Abandon it. Whether you agree with his conclusions or strongly disagree, this episode asks questions that Nicolas Hulscher believes parents, physicians, researchers and regulators should be willing to confront.

Moderna (MRNA) and its "overexuberant" breakout takes Patrick Ciummo of Charles Schwab's focus. He shows how the 30-day price action ran hot and how it sets the stage for a likely cooldown in the coming sessions. ======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

Citi downgraded Moderna (MRNA) following the stock's astronomical rally in recent weeks. Boeing (BA) pens a $20 billion deal with the U.S. Navy for its next generation fighter jets. Jabil (JBL) shares didn't move much on its earnings beat and strong guidance. Diane King Hall turns to the biggest stories moving markets following Wednesday's opening bell. ======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of transformative developments across the pharmaceutical and biotech sectors, highlighting strategic investments, innovative therapies, and regulatory milestones. AstraZeneca's recent $2 billion investment in Summit Therapeutics is a testament to the industry's focus on cutting-edge oncology solutions. This substantial funding aims to advance the development of ivonescimab, a PD-1xVEGF bispecific antibody, in conjunction with antibody-drug conjugates. This strategic move underscores the potential of combining different therapeutic modalities to target complex cancer pathways, particularly in gastrointestinal malignancies. By leveraging dual-targeting capabilities, these therapies promise enhanced efficacy, marking a significant step forward in cancer treatment paradigms. Meanwhile, Novo Nordisk is making strides in metabolic disease management through its partnership with Hengrui Pharma. This collaboration to develop a weekly oral GLP-1R/GIPR dual agonist for obesity underscores the growing emphasis on innovative metabolic therapies. The upfront payment of $300 million, with additional milestone payments potentially reaching $2.6 billion, reflects the high stakes involved in addressing obesity—a global health challenge. This approach could revolutionize current treatment standards by improving patient compliance and outcomes through targeted small molecule interventions. On the manufacturing front, Genentech's $750 million expansion of its Hillsboro facility highlights the increasing demand for biopharmaceuticals. This investment is poised to double the facility's size by 2031, supporting new drug approvals in oncology, neurology, and immunology. Enhanced production capacity is crucial for meeting the intricate requirements of biologics and personalized medicine, ensuring that breakthrough treatments reach patients more effectively. In the realm of antibody research, Ginkgo Bioworks, AbbVie, and Takeda have joined forces to form the Antibody Developability Consortium. By creating a standardized dataset for antibody development using artificial intelligence and machine learning, this initiative aims to streamline the discovery and manufacturability of therapeutic antibodies. The collaboration seeks to overcome existing challenges in antibody drug development, potentially expediting time-to-market for new therapies. In neurology, AC Immune's Phase 2 trial of ACI-7104 has shown promising results in early-stage Parkinson's disease by meeting all primary endpoints and demonstrating complete immunogenicity. This active immunotherapy targeting alpha-synuclein presents hope for modifying disease progression rather than merely alleviating symptoms. Such advancements highlight the potential of vaccination strategies in addressing neurodegenerative diseases. Roche is also embracing innovation by planning autonomous AI labs for drug R&D. These labs are expected to accelerate clinical candidate development significantly, reducing costs while improving success rates in bringing new drugs to market. This initiative exemplifies how AI-driven drug discovery is reshaping research methodologies. Despite these advancements, challenges persist within the industry. UniQure's gene therapy for Huntington's disease showed diminished effectiveness over four years in Phase 1/2 trials, illustrating the complexities inherent in developing neurological disorder treatments. Additionally, BioNTech's closure of three sites in Germany resulting in substantial job cuts highlights broader economic pressures despite its success with mRNA vaccines. Regulatory developments are crucial as well. The FDA's approval of Roche's Gazyva for idiopathic nephrotic syndrome marks a pivotal advancement as it becomes the first treatment option for this condition in 70 years. This approval not only provides hope for patients but also sets a precedent for future research into autoimmune diseases. In contrast to these successes, Roche decided to discontinue its muscle-sparing obesity antibody following disappointing phase 2 results. Such outcomes emphasize the importance of interim analyses and adaptive strategies in drug development. Overall, these updates underscore a dynamic period characterized by strategic investments, technological innovation, and collaborative efforts aimed at addressing some of healthcare's most pressing challenges. The integration of cutting-edge technologies such as AI and novel therapeutic modalities continues to drive progress towards more effective and personalized patient care solutions. As we wrap up today's episode of Pharma Daily, it's clear that while opportunities abound within the industry through scientific breakthroughs and strategic collaborations, challenges remain that require careful navigation. Companies that balance innovation with rigorous clinical evaluation will be at the forefront of delivering transformative healthcare solutions globally. Thank you for tuning into Pharma Daily; stay informed with us as we continue to track these evolving trends shaping the future of pharmaceuticals and biotech.Support the show

THE TIM JONES AND CHRIS ARPS SHOW 0:00 SEG 1: SPEAKER'S STUMP SPEECH is brought to you by https://www.hansenstree.com/ “The War on Poverty Has Been An Epic Waste” 20:39 SEGMENT 2: DR. RANDY TOBLER, Host of The Randy Tobler Show on NewsTalkSTL Saturday mornings from 6-9 and co-host of Wake Up Missouri weekdays on 93.9 The Eagle in Columbia || TOPIC: News of the day || The first mRNA flu vaccine is now available for older adults || America.gov websitex.com/RandyToblerMDbodyofhealth.com/ 35:23 SEGMENT 3: Lindsay Clancy lawyer says there is no evidence she killed her kids https://newstalkstl.com/ FOLLOW TIM - https://twitter.com/SpeakerTimJones FOLLOW CHRIS - https://twitter.com/chris_arps 24/7 LIVESTREAM - http://bit.ly/NEWSTALKSTLSTREAMS RUMBLE - https://rumble.com/NewsTalkSTL See omnystudio.com/listener for privacy information.

THE TIM JONES AND CHRIS ARPS SHOW 0:00 SEG 1: SPEAKER'S STUMP SPEECH is brought to you by https://www.hansenstree.com/ “The War on Poverty Has Been An Epic Waste” 20:39 SEGMENT 2: DR. RANDY TOBLER, Host of The Randy Tobler Show on NewsTalkSTL Saturday mornings from 6-9 and co-host of Wake Up Missouri weekdays on 93.9 The Eagle in Columbia || TOPIC: News of the day || The first mRNA flu vaccine is now available for older adults || America.gov websitex.com/RandyToblerMDbodyofhealth.com/ 35:23 SEGMENT 3: Lindsay Clancy lawyer says there is no evidence she killed her kids https://newstalkstl.com/ FOLLOW TIM - https://twitter.com/SpeakerTimJones FOLLOW CHRIS - https://twitter.com/chris_arps 24/7 LIVESTREAM - http://bit.ly/NEWSTALKSTLSTREAMS RUMBLE - https://rumble.com/NewsTalkSTL See omnystudio.com/listener for privacy information.

Become a supporter of this podcast: https://www.spreaker.com/podcast/cult-of-conspiracy--5700337/support.

Following the death of 27-year-old Presley Gerber inside a Santa Monica sober living facility, board-certified psychiatrist and former FDA Medical Officer Dr. Josef Witt-Doerring of TaperClinic joins Dr. Drew to examine the fatal risks of overmedicating with psychiatric drugs. Dr. Witt-Doerring analyzes Gerber's disclosures of fluctuating benzodiazepine doses without daily medical oversight, the physiological hazards of unmonitored psychiatric medication tapers, and the emerging panic over gas station kratom. Dr. Mary Talley Bowden breaks down the brewing revolt within the MAHA movement, as health freedom leaders issue an ultimatum to Pres. Donald Trump and RFK Jr. demanding the removal of the mRNA vaccine platform. California Department of Public Health whistleblower Ronald Owens Jr., author of “Muzzled Truth,” exposes how state officials suppressed early COVID-19 treatment warnings from 40 million residents and examines former HHS Secretary Xavier Becerra's controversial public remarks on vaccine mortality. Dr. Mary Talley Bowden completed her residency at Stanford University and is board-certified in both Otolaryngology and Sleep Medicine. She is the author of “Dangerous Misinformation: The Virus, the Treatments, and the Lies” available at https://amzn.to/4rF16CW. Follow at https://breathemd.org Ronald F. Owens, Jr. worked at the California Department of Public Health (CDPH) as an Information Officer 2 during COVID, where he says he learned that then-HHS Secretary Xavier Becerra said COVID-19 vaccines were “killing people.” He is the author of “Muzzled Truth: How The California Dept. of Public Health Rejected COVID-19 Treatment and Vaccine Health Risks Warnings.” Find more at https://muzzledtruth.com Dr. Josef Witt-Doerring is a board-certified psychiatrist and former FDA Medical Officer who is Medical Director of TaperClinic, one of the only practices focused exclusively on helping patients safely de-prescribe from psychiatric medications. He previously worked at Janssen Pharmaceuticals and the FDA's Division of Psychiatry, and hosts the podcast Side Effects with Dr. Josef. Follow at https://taperclinic.com 「 SUPPORT OUR SPONSORS 」 • FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/fatty15⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/paleovalley⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twc.health/drew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 「 ABOUT THE SHOW 」 This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Executive Producers • Kaleb Nation - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • Susan Pinsky - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/firstladyoflove⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Content Producer • Emily Barsh - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/emilytvproducer⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Day Break | America on Alert: Terror, China & the Midterm Showdown --- 00:00 - Monologue 19:07 – Mario Kranjac, former Mayor of Englewood Cliffs, New Jersey. Kranjac discusses a voter-registration controversy in New Jersey and the questions it has raised about the accuracy and maintenance of the state's voter rolls. He examines election administration, registration procedures, and concerns being raised ahead of upcoming elections. 28:05 – Dr. Mary Talley Bowden, Stanford-trained ear, nose, and throat physician based in Houston, Texas. Dr. Bowden discusses criticism from some figures associated with the Make America Healthy Again movement over the Trump administration's approach to mRNA vaccines. She examines disagreements over vaccine policy, the roles of President Trump and HHS Secretary Robert F. Kennedy Jr., and why some activists say the issue could carry political consequences. 38:18 - Monologue Featuring Ivey Gruber 47:16 – Katie Asher, vaccine researcher and author of The Book of Heaven: A Story of Hope for the Outcasts, the Broken, and Those Who Lost Faith. Asher discusses controversy surrounding a state initiative involving home visits for families with newborn babies. She examines concerns raised by critics about parental rights and government involvement in the home, as well as the stated public-health goals behind such programs. 57:30 – Houston Keene, Director of Democracy Restored. Keene discusses his organization's request that the Department of Homeland Security review its contracts with Microsoft following remarks attributed to a former FBI official about a “shadow government.” He examines the watchdog group's concerns about federal contracting, political activity, and potential conflicts of interest. 1:06:29 – Lindsay Porzio, Director of Stic-It Rotating Flags. Porzio discusses what she sees as a renewed enthusiasm for patriotism and displays of the American flag, including in traditionally Democratic-leaning states. She explores changing cultural attitudes toward national pride and why patriotic imagery appears to be resonating with a new generation of Americans. 1:16:34 - Monologue 1:25:32 – Melanie Kurdys, Board Member of United States Parents Involved in Education and President of the organization's Michigan chapter. Kurdys discusses concerns about Chinese Communist Party influence and what she describes as “cognitive warfare” within K-12 schools and higher education. She examines foreign influence, educational partnerships, curriculum, and efforts aimed at protecting American students and institutions. 1:35:33 – Gordon G. Chang, author of Plan Red: China's Project to Destroy America, The Coming Collapse of China, and China Is Going to War. Chang discusses Xi Jinping's visit and meeting with President Trump, focusing on the major economic and national-security issues shaping U.S.-China relations. He examines trade, strategic competition, China's global ambitions, and what the meeting could mean for relations between Washington and Beijing. 1:44:20 – Ivey Gruber, President of the Michigan Talk Network. Gruber joins Steve to close out the show with conversation and commentary on the day's news, politics, culture, and other stories making headlines. --- Check out our podcast, 'Forgotten America'... Episode 24 is live NOW at Steve Gruber on YouTube! Link below: https://youtu.be/UrGZQdE62jA

Who gets to read the science, and who pays for it? Fresh back from summer (tans included),  Garry Aslanyan and co-hosts  Catherine Kyobutungi and Ricardo Baptista Leite return for the fifth installment of The Inside Track. This time they're joined by special guest Ashley Farley, Senior Officer for Knowledge and Research Services in Global Health at the Gates Foundation, to dig into open access and the paywalls that keep research away from the people who need it most. They talk about why the Gates Foundation stopped paying article processing charges and the growth of Diamond Open Access. The pundits then pick apart Lithuania's controversial plan to send newly trained doctors to rural areas. They close with kudos for El Salvador eliminating trachoma, promising mRNA cancer vaccine results and the public health thinking behind Addis Ababa's makeover.Related episode documents, transcripts and other information can be found on our website.Subscribe to the Global Health Matters podcast newsletter.  Follow us for updates:@TDRnews on XTDR on LinkedIn@ghm_podcast on Instagram@ghm-podcast.bsky.social on Bluesky  Disclaimer: The views, information, or opinions expressed during the Global Health Matters podcast series are solely those of the individuals involved and do not necessarily represent those of TDR or the World Health Organization.    All content © 2026 Global Health Matters.

In Yemen, fighting is intensifying around the Yemeni city of Taiz, where government forces are trying to halt a new advance by Houthi fighters closing in on the city. We have a frontline report from the BBC's international investigations correspondent. Also on the programme: investigations continue into a suspected terror plot at an air force base in southern England; and a potential breakthrough in the storage of mRNA vaccines, which could revolutionise rural healthcare.(Photo: A displaced Yemeni woman, Fatma Mohammed Saleh, speaks to the BBC. Credit: Liam Weir/BBC)

The introduction of an mRNA seasonal flu vaccine is creating new questions for public health communicators about vaccine hesitancy, misinformation, and how to build confidence in vaccination. Jessica Malaty Rivera, executive director of the Infodemiology Initiative at Public Good Projects, discusses the questions and concerns emerging around the new mRNA flu vaccine, including how existing doubts about mRNA vaccines may be influencing perceptions of flu vaccination. She explains why communicators should focus on providing clear information about who the vaccine is for, what people can expect, and what is known about its safety and side effects rather than trying to respond to every circulating false claim. Rivera also discusses communication strategies such as pre-bunking and the “truth sandwich,” and how public health agencies can encourage questions and curiosity while keeping evidence-based information at the center of the conversation.First mRNA flu vaccine brings COVID-era concerns into flu vaccine conversations | Infodemiology.comPower Hour PLUS: Expand Your Impact | ASTHOPower Hour PLUS: Expand Your Impact - Session 1 - From Urgency to Action: Advancing Decision-MakingASTHO Welcomes Lindsey Myers, Jane Bigham, and Jeffrey Ekoma to New Leadership Roles | ASTHO

Send us Fan Mailhttps://soreadyforhealth.podia.com/Support the show

Send us Fan MailBook a consult today!soreadyforhealth.comTelegram Channel: soreadyforhealthSupport the show

В този епизод на Ratio Weekly Петко и Никола Кереков обсъждат как пластмасови бутилки и отпадъци от царевични растения могат да бъдат превърнати в ядливи бисквити с ванилов вкус чрез комбинация от химична обработка и генетично модифицирани дрожди. Засега учените очакват необходимите разрешения, за да могат да опитат резултата от експеримента. След това се отправят към Китай, където експериментален влак успява да достигне 800 км/ч само за 5,3 секунди – рекорд, който може да помогне за развитието на технологии за високоскоростен транспорт, космически системи и други приложения. Разказват и за най-бързия паяк в света и необичайния начин, по който се движи, за да преследва плячката си. А в медицинската част на епизода става дума за персонализирана mRNA ваксина срещу рак на панкреаса, създавана според мутациите в тумора на конкретния пациент. В малко клинично изпитване ваксината е активирала специфични Т-клетки при половината от участниците, като 7 от 8-те пациенти с такъв имунен отговор са били живи 4–6 години след лечението. Резултатите са предварителни, но вече се провежда по-голямо проучване, което да покаже дали подходът може да работи при повече пациенти. Гледай епизода тук: https://youtu.be/BqDF2XxLcqk Споделено в епизода: Учени превръщат пластмасови бутилки във ванилови бисквити (тук) Най-бързия влак в света тестваха в Китай (тук) Най-бързият паяк в света (тук) Противоракова ваксина за меланома (тук) Ваксина за панкреатичен рак показва много добри резултати (тук) За подкаста: В епизодите на Ratio Weekly, нашата импровизирана научна новинарска емисия, молекулярният биолог Никола Кереков в компанията на харизматичния водещ Петко Желязов ви представят най-новите открития и най-любопитните постижения в сферата на науката, технологиите и медицината от изминалата седмица. В тази мини-серия на Ratio Podcast говорим за неща като това как да общуваме ефективно с котките, защо китовете се самоубиват и какво живее на Венера. Това е една от шестте серии на Ratio Podcast – един подкаст за любопитни хора. С негова помощ ще си сверите часовника за всичко най-ново в света на науката и културата и ще чуете неформални разговори, свързани или вдъхновени от наука.

Waardeer je onze video's? Steun dan Café Weltschmerz, het podium voor het vrije woord: https://www.cafeweltschmerz.nl/doneren/Geen scan, geen paspoort: gemeenten verplichten gezichtscontrole met AIIn week 39 oefenden militairen met abseilen op het dak van ziekenhuis Antonius IJsselmonde.De AIVD en MIVD willen spionage op burgers legaliseren.Ministers mogen straks zelf toestemming geven voor ingrijpende besluiten.Een rechter komt er niet meer aan te pas.Een voormalige inlichtingenbaas waarschuwde voor de privacy en de bureaucratie.Rob Jetten schudde Al Jolani de hand.Volgens Geesje Rotgers hebben bramen en brandnetels geen last van stikstof.Onderzoek koppelt complotdenken aan mentale problemen; Jeroen en Willem draaien die vraag om.Op 29 september begint in Luxemburg de zitting over David Icke.Het Hof buigt zich over de vraag of hij een strafbaar feit pleegde.De achterban van Kennedy eist dat mRNA van de markt gaat.Christian Eriksen stopt per direct met voetballen na een hartinfarct.Trump ontzegt journalisten het Witte Huis en trekt de VS uit de VN-Mensenrechtenraad.Van het dak van IJsselmonde tot de rechtszaal in Luxemburg verschuift deze week de grens van wat mag.Deze video is geproduceerd door Café Weltschmerz. Café Weltschmerz gelooft in de kracht van het gesprek en zendt interviews uit over actuele maatschappelijke thema's. Wij bieden een hoogwaardig alternatief voor de mainstream media. Café Weltschmerz is onafhankelijk en niet verbonden aan politieke, religieuze of commerciële partijen.Wil je meer video's bekijken en op de hoogte blijven via onze nieuwsbrief? Ga dan naar: https://www.cafeweltschmerz.nl/videos/Wil je op de hoogte worden gebracht van onze nieuwe video's? Klik dan op deze link: https://bit.ly/3XweTO0

In his weekly clinical update, Daniel Griffin and Vincent Racaniello frustration continues over the increasing number of measles infections, Kennedy's undermining of vaccines, perpetuation of autism- vaccine, autism-tylenol myths, an outbreak of hepatitis A virus in the US, the Ebola outbreak in Uganda, changes in reporting of virus infection and vaccine recommendations, Legionnaires disease and screw worm cases, and before Dr. Griffin deep dives into recent statistics RSV, influenza, SARS-CoV-2 infections, economics of a measles outbreak in Chicago, what defines reactogenicity of the mRNA COVID vaccines, the on-going delay by HHS of COVID shots for children, neuropsychiatric symptoms of long COVID and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode CDC adds 177 cases to US measles total but has yet to confirm deaths in Pennsylvania (CIDRAP) Kennedy questions vaccine safety at Children's Health Defense event (CIDRAP) Trump says some routine immunizations will be split into five separate shots. Vaccine experts say it won't work (CNN) Multistate Hepatitis A Outbreak Potentially Linked to Frozen Clams (CDC: Hepatitis A) Cumulative Incidence and Prevalence of Autism Spectrum Disorder (JAMA Pediatrics) Data and Statistics on Autism Spectrum Disorder (CDC: Autism Spectrum Disorder) Study uncovers no evidence of autism epidemic, despite claims (CIDRAP) Florida confirms a death from dengue as the state struggles with one of its worst recent outbreaks (AP News) Legionnaires' Disease (NYC: Health) Dashboard SCREWWORM.Gov (USDA: Animal and Plant Health Inspection Service) CDC Activates Emergency Operations Center for New World Screwworm Response (CDC Newroom) Democratic Republic of Congo (AP News) Ebola virus (AP News) Congo begins Ebola vaccinations for health workers in the epicenter of the outbreak (AP News) Ebola dashboard (ebola.fyi) EBOLA: The Democratic Republic of the Congo, 2026 (WHO) Bundibugyo virus disease outbreak Democratic Republic of the Congo(WHO: Democratic Republic of Congo) Ebola Outbreak: Current Situation (CDC:Ebola) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Big outbreak, bright lights…Measles Dashboard (South Carolina Department of Public Health) Utah measles outbreak response (Utah Department of Health and Human Services) Utah Measles Dashboard (Utah Department of Health and Human Services) Measles (VDH: Virginia Department of Health) Tracking Measles Cases in the U.S. (Johns Hopkins) HAP's Latest News Pa. Launches New Measles Dashboard (Hospital + HealthSystem Association of Pennsylvania) Measles (Commonwealth of Pennsylvania) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Pennsylvania asks CDC for emergency assistance amid RFK Jr. clash over measles(The Hill) Pennsylvania measles-associated deaths climb to four as outbreak grows (Reuters) Pennsylvania asks for CDC measles help amid Kennedy dispute (Reuters) Republican senator faults Trump vaccine policy for US measles deaths as panel weighs health nominees (Reuters) US CDC works on standard definition for measles deaths as cases rise (Reuters) Cost of a Measles Outbreak in an Urban Shelter (JAMA Open Network) Measles outbreak in Chicago shelter cost nearly $9 million, CDC estimates (CIDRAP) World's most contagious virus hits major US airport as officials warn of possible exposure (FoxNews) Measles Cases and Outbreaks (CDC: Rubeola) Laboratory Testing for Measles (CDC: Measles (Rubeola) Measles Clinical Diagnosis Fact Sheet (CDC: Measles (Rubeola) Measles Serology Testing (CDC: Measles (Rubeola) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Flu vaccine recommendations: Vaccines and Related Biological Products Advisory Committee March 12, 2026 Meeting Announcement (FDA) WHO updates all 3 viral strains to be included in fall flu shots(CIDRAP) FDA vaccine advisers recommend adding subclade K to fall shots(CIDRAP) Weekly surveillance report: cliff notes (CDC FluView) OPTION 2: XOFLUZA $50 Cash Pay Option (xofluza) Immunogenicity and safety of an MF59-adjuvanted cell-derived higher-dose quadrivalent influenza vaccine (aQIVc) in adults aged 50 years or older: a phase 3 randomised controlled trial (LANCET: Infectious Diseases) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) RSV Immunization Effectiveness and Safety for the 2026-2027 Respiratory Season (JAMA) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines (Moderna) Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season (novavax) Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine (Pfizer) FDA approves new COVID vaccines (CIDRAP) Baseline interferon signaling in monocytes and antibody-mediated innate activation are associated with reactogenicity to mRNA vaccines (Science Translational Medicine) Coronavirus Disease 2019 (COVID-19) Hospitalization Surveillance Network (COVID-NET)(CDC: Covid) CDC inaction delays COVID shots for low-income children (CIDRAP) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Loss of vesicular monoamine transporter 2 in striatum of long COVID and relationship to neuropsychiatric symptoms (eBioMedicine) Reaching out to US house representative Letters read on TWiV 1360 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Jordan and Nate open with a genuinely stunning admission from RFK Jr: HHS is formally investigating chemtrails and electromagnetic frequency exposure, complete with a federal request for public input. They debate whether AI can actually "cure" disease or just deliver smarter treatments, cheer a new FDA rule cutting mandatory animal testing, and cover fresh executive orders opening federal land to hunters and reviving old school incandescent light bulbs. A story about Massachusetts mandating government home visits for new parents sparks a genuinely uneasy conversation about where that could lead. From there it is straight into fraud territory, with J.D. Vance's Obamacare crackdown and Dr. Oz's clash with activist groups, followed by a nuanced look at new GLP1 vision loss lawsuits and a media fueled Kratom panic the guys pick apart in real time. They close with a candid, occasionally skeptical breakdown of a MAHA coalition's open letter demanding an mRNA vaccine ban.  

NEW: Send us Your Comments!This Week's Topics:Trump Challenges the UN & Makes Deals 3:00Tump-Xi Summit Produces Stability 9:00Tump will Not Agree to Regulate AI 12:00China Threat is NOT Killer Robots! 13:30Congress: China Behind Anti-Datacenter Efforts 17:00Media Citing Chinese Sources DataCenter Study 19:30China is Building it's own Chips to Beat US! 21:30Trump Plans to Name “AI CZAR” 24:30Should We Put Data Centers on Public Land? 27:00The TRUTH about Why Diesel is $6.00 Gallon!  29:30Ohio to FINALLY Suspend Fuel Tax! 35:00South Korea Funds $20 B Gas Project in TX 39:30US May do Huge LNG Deal with China 41:30POLL: Socialism Isn't that Popular 43:30Dems Ditching Mail-in Ballots 46:30Dems will do ANYTHING to Get Rid of Trump! 54:30Left is Studying MAHA Moms to Change Votes 57:00SCOTUS Approves use of SAVE Database 1:00:00300 DOJ Attorney's Quit! GOOD! 1:05:00200 Election Fraud Arrests 1:10:00Illegals are Exiting US Banking System 1:14:00Paid For Anti-Ice Protests in Austin 1:16:00ICE Officer Assaults up to 647 from 37 1:18:30Houston Schools Lose 21 K Illegal Students 1:21:30760,000 Fake Obamacare Enrollees Cancelled 1:24:00Medicare Over-Paid for Lab Tests for Years 1:28:30MAHA Warns Trump and RFK Jr about mRNA 1:32:00Hacker Group Steals FBI Personnel Files 1:34:30More Hospitals Quit Child Mutilations 1:36:00US Deploys Anti-Drone Lasers in Iran War 1:39:00VIDEO: Be Inspired by NASA's Future! 1:41:00Trump Uses “Pocket Rescission” 1:44:00Hand out our 2026 Election Flyers! 1:47:30Find Locations for Barn Billboards! 1:50:30Support the showView our Podcast and our other videos and news stories at:https://wethepeopleconvention.org/Podcast-Player-PageSend Comments and Suggestions to:info@WethePeopleConvention.org

Despite campaign promises to clean up the health agencies, the reality on the ground is moving rapidly backwards. Dr. Robert Malone reveals how industry insiders are quietly replacing battlefield-tested medical freedom fighters at the CDC and FDA. Instead of rolling back disastrous health interventions, the government is doubling down: approving new mRNA COVID shots and pushing the first mRNA flu vaccines. This isn't accidental — it's a calculated regulatory maneuver to officially cement mRNA as a legally recognized "platform technology," guaranteeing a permanent, highly lucrative monopoly for Big Pharma giants like Pfizer and Moderna while boxing out safer alternatives. In a wide-ranging discussion, Dr. Malone and I warn how the medical freedom betrayal is emblematic of the broader political Right, whereby the very influencers who talk an issue to death actually turn around and become enforcers for the other side when the ball is in play. This creates a vicious cycle: Politicians make promises, influencers defend them and tell the base to stand down, and the promised reforms never happen — or policy moves backward. Oh, and anyone demanding accountability is accused of helping the Democrats, even as the GOP perfidy itself is what is helping the Democrats win.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Mary Holland, CEO of Children's Health Defense, draws a straight line from the 1986 National Childhood Vaccine Injury Act — which stripped liability from manufacturers — to the 2005 PREP Act, to COVID, to the mRNA shots being added to the childhood schedule specifically to preserve liability protection before the emergency expired. CHD's position is unambiguous: COVID shots should not be on the market, the RNA technology has not been proven safe at population scale, and no vaccine mandated without stopping transmission has any ethical justification. Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code “KNIGHT” For high quality made in America products go to HomeSteadProducts.shop and use promo code “Knight” for 10% off your purchases Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

Mary Holland, CEO of Children's Health Defense, draws a straight line from the 1986 National Childhood Vaccine Injury Act — which stripped liability from manufacturers — to the 2005 PREP Act, to COVID, to the mRNA shots being added to the childhood schedule specifically to preserve liability protection before the emergency expired. CHD's position is unambiguous: COVID shots should not be on the market, the RNA technology has not been proven safe at population scale, and no vaccine mandated without stopping transmission has any ethical justification. Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code “KNIGHT” For high quality made in America products go to HomeSteadProducts.shop and use promo code “Knight” for 10% off your purchases Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

My co-host Ken Suzan and I are welcoming you to episode 179 of our podcast IP Fridays! Today's Interview guest is Peter Berg. If you don't know Peter, he is the Chief IP Counsel at Infineon Technologies and is also serving as the VPP president. We talk about the industry association of in-house practitioners VPP, politics, patent strategy at Infineon, litigation ready patents, NPEs, acquisitions, the German emloyees invention act and many more things. So stay with us for this very interesting interview. Before we jump into this interview, I have news for you! The USPTO has issued its first AI-related disciplinary action, published on August 27, 2026 in In re Brian E. Mitchell (Proceeding No. D2026-16) before the Office of Enrollment and Discipline. The underlying settlement was signed by the attorney on July 20, 2026 and by the OED Director on July 21, 2026, with final approval given on July 27, 2026 by Tricia Choe on behalf of USPTO Director John A. Squires. The action resulted in a public reprimand against California patent attorney Brian E. Mitchell after a generative AI tool produced a claim comparison chart containing fabricated citations to the patent’s internal file history. The case underscores that AI-generated hallucinations must be verified by a human before filing. InterDigital has escalated its patent dispute with Disney across three fronts within a month. On August 25, 2026, InterDigital filed two new actions at the Unified Patent Court: a preliminary injunction request at the Mannheim Local Division (UPC_CFI_3044/2026) and a main infringement action at the Düsseldorf Local Division (UPC_CFI_3043/2026), covering Germany, France and the Netherlands. Both target Disney+ Premium’s switch to the VP9 video codec, which InterDigital says still infringes patent EP 2 465 265, a patent the Mannheim division had already found valid and infringed in an earlier ruling that also branded Disney an unwilling licensee; the Düsseldorf action adds a second patent, EP 2 605 473, covering the Up Next continue-watching feature. On September 2, 2026, the Düsseldorf Local Division granted InterDigital an injunction against Disney covering Germany and the Netherlands over a separate patent protecting seamless playback continuation when switching between devices, upholding the patent’s validity in the same ruling. It was InterDigital’s third UPC injunction against Disney. Then, on September 15, 2026, InterDigital filed a damages claim for EUR 101.7 million against Disney at the Munich Regional Court I (case no. 7 O 8870/26), based on a November 2025 finding that Disney+ infringes InterDigital’s HDR video patent EP 2 132 923; the claim also covers viewers in 19 European countries served through a Frankfurt-based server location. For companies relying on codec or connectivity technology, the dispute is a reminder that switching to a different standard does not automatically avoid infringement if the asserted patent is drafted broadly enough. The EPO’s Enlarged Board of Appeal ruled on September 3, 2026 in G 1/25 that a patent description only needs to be amended to match amended claims if a discrepancy between the two causes a requirement of the EPC, such as clarity, novelty or inventive step, not to be met. The EPO’s Board of Appeal 3.3.08 fully revoked Moderna’s key mRNA patent EP 3 590 949 following a two-day hearing that concluded in mid-September 2026, on the grounds that the claimed subject matter extended beyond the original application. The revocation removes the basis for Moderna’s earlier wins against BioNTech and Pfizer in Düsseldorf and London. On September 15, 2026, US sportswear maker New Balance filed a trademark suit against Decathlon’s US units, Decathlon America LLC and Decathlon USA LLC, in the US District Court for the District of Massachusetts (case no. 1:26-cv-14235). New Balance argues that the K logo on its Kiprun running shoe line, when mirrored, reads unmistakably as an N and imitates the N mark it has used for roughly 50 years, claiming post-sale confusion. On September 8, 2026, the Court of Justice of the EU ruled in Case C-298/23, Inter IKEA Systems v Vrijheidsfonds, on a referral from the Brussels Enterprise Court, that the owner of a well-known trademark can prohibit its use by a political party unless the party sets out the specific reasons why its freedom of expression outweighs the trademark owner’s interests. The case arose from the Vlaams Belang party’s 2022 campaign promoting a migration plan styled as IKEA assembly instructions. And now for the interview with Peter Berg! In this episode of IP Fridays I talk with Peter Berg. He is Chief IP Counsel at Infineon Technologies and President of VPP, the German association for in house IP professionals, since May 2025. Berg is an electrical engineer by training and leads a team at Infineon that manages a portfolio of more than 12,000 patent families, while the company simultaneously enforces its rights offensively in Germany, the US and China. That combination of hands on portfolio work and association leadership makes him one of the rare guests who can speak to both the operational detail of one of Europe’s largest patent portfolios and the political side of Germany’s IP landscape. The guest: Peter Berg and the VPP Peter Berg is an electrical engineer who became Chief IP Counsel at Infineon Technologies and, since May 2025, President of the VPP, the association representing in house patent professionals in Germany. His team manages a portfolio of more than 12,000 patent families while running an offensive enforcement program across Germany, the US and China. That mix of operational and political experience is exactly why I wanted him on the podcast. Germany’s national IP strategy: more than a promise on paper I asked Berg what has become of the national IP strategy promised in Germany’s coalition agreement, and what happens if it does not materialize during this legislative term. His answer was clear. The question is no longer whether the strategy will arrive, only how comprehensive it turns out to be. If it falls short of what industry needs, the profession will simply push for adjustments afterward. Berg names three levels that need attention. First, society as a whole, from kindergarten to retirement, needs to understand that intellectual property underpins our prosperity rather than being a line item in the accounts. Second, academia and professional education. Third, startups and the broader Mittelstand, where well funded structures are still missing. The German Patent and Trademark Office has an educational mandate but far too small a budget for it, and the regional patent information centers are underfunded as well. Berg makes a point that is easy to miss from outside Germany: the patent office reports to the Ministry of Justice rather than to an innovation focused ministry, even though its real purpose is to strengthen the economy. That three ministries, research, economy and justice, are now working on the strategy together strikes him as genuine progress. Litigation ready patents: how Infineon manages 12,000 patent families Infineon has roughly tripled its turnover since 2017 while keeping portfolio size largely stable. The answer, Berg says, is quality over quantity. Inventors pitch their ideas to a panel of senior technical experts and patent attorneys, and the process does not stop there. The draft itself is reviewed by multiple stakeholders, and once the notice of allowance arrives and the patent is granted, it goes through another review. The criteria stay consistent throughout: technology assessment, market size, detectability, circumventability and fit with Infineon’s own roadmap. Internal discipline alone does not make a patent litigation ready, though. That requires real experience with conflict, and most of that experience comes from the defensive side, where Infineon has plenty of practice finding weaknesses in patents asserted against it. Being on the offensive, Berg says, is a different level of learning entirely, whether in court or in licensing negotiations where the other side is not sure it would get a fair outcome if the case went to trial. In practice this also means systematic pruning. Internally Infineon calls the relevant phases US8 and US12, the years when annuity costs peak in the US portfolio, by far the most expensive part of the estate. Berg says his team knows every one of the more than 12,000 patent families in detail, and offensive enforcement is focused on the markets that matter most for electronic products: Germany, the US and China. An injunction at a trade show: national courts versus the UPC One concrete trigger for this conversation was an ex parte preliminary injunction Infineon obtained at a German trade show, without the defendant having filed a protective letter in advance. For Berg, enforcement at trade fairs is nothing new, it has been part of the playbook for years, now extended to venues outside Europe that Western companies have used less often in the past. His view on the UPC is nuanced. He credits the court with a strong start, good management and judges selected for quality rather than politics, and praises the body of case law it has built in a little over three years. On the other hand, some member states are still missing, a comprehensive body of case law takes time to develop, and costs do not fit every business case, especially where achievable damages barely justify the expense. Infineon in any case validates most European patents in only a handful of countries rather than dozens, so the practical difference between national and UPC enforcement is smaller than it might seem. For smaller cases the option to opt out and litigate nationally alongside UPC rights remains important, even though systematically double patenting is not something Infineon pursues for cost reasons. Four systems at once: coordinating cross border enforcement Infineon’s legal and patent departments have grown together over 25 years into a fully integrated international organization, with teams in Europe, North America and several Asian countries that, by Berg’s account, communicate on close to a weekly basis. Add to that a strong network of outside counsel. The commitment to management is not to shy away from any jurisdiction where the need arises. Berg is careful that patent attorneys do not spend their entire careers doing only litigation or only prosecution. Attorneys who rotate into a litigation team bring that experience back into their regular business support afterward, and that cycle in turn improves the quality of new filings. Litigation has become part of daily business, but never something a team slides into unprepared. Going on the offensive against a competitor requires planning several steps ahead. IP due diligence in practice: the Marvell Brightlane deal I found Berg’s answer on the Marvell Brightlane acquisition, Infineon’s 2.5 billion dollar deal for Marvell’s automotive Ethernet business that closed in August 2025, particularly revealing. In the semiconductor industry, he explains, IP is rarely primarily the patent portfolio. What matters more are frozen technologies and so called IP blocks, reusable design blocks that enable fast product development. Infineon almost never acquires a company because of its patents. Being a large, established player, its own portfolio is usually broad enough to secure a new technical area against incumbent competitors. The real work starts after signing. It means listening without being pushy, understanding the new colleagues’ processes and tools before deciding how to integrate the portfolio. Since none of Marvell’s IP staff joined Infineon in this deal, the team had to build up portfolio expertise using the acquired engineers and set up an operational patent committee, then plan which areas of the portfolio were already strong and where investment was still needed. The faster that integration decision gets made, Berg says, the better, because product development can never be allowed to stall because of an acquisition. The Cypress lesson: NPE exposure from legacy portfolios One risk many companies underestimate in acquisitions is patents an acquired business sold to a non practicing entity, or NPE, before the deal closed. That happened with Cypress Semiconductor in 2016, after its merger with Spansion left it with an oversized portfolio it did not need. Cypress sold around 2,000 patents to the NPE organization IP Value, and only a few years later Infineon acquired Cypress. Because the sale included a retained license for Cypress’s own business, Berg sees no exposure for Infineon from those specific patents today. The broader issue of NPE enforcement, though, remains real. Realistically there are many dozens of new cases a month, often directed at customers or the wider ecosystem rather than at chipmakers directly. Even when Infineon is not the target, it has to support its customers whenever its own technology is implicated. For the industry as a whole this consumes a great deal of resources without moving innovation forward, a point that comes up especially often at this time of year in Munich, when IP practitioners from around the world gather for meetings. Post quantum cryptography: patent density ahead of standardization In December 2024 Infineon became the first company to achieve a CC EAL6 certification in post quantum cryptography, one of the highest security certifications available. Berg describes two angles to the work. On one side, Infineon develops its own chipsets to enable quantum computing itself, already a real business rather than pure research. On the other side, customers across Infineon’s application fields need to be prepared for what he calls quantum day, the point at which powerful quantum computers become available, including to bad actors. Because that day may only be three to five years away, infrastructure needs to be built now so it can handle new cryptographic approaches. On standard essentiality he is measured rather than evasive. There are certainly patents in this field from Infineon and others, but security standards have historically leaned toward royalty free licensing rather than the large patent clusters seen in cellular communication from 2G through 5G. Whether that pattern repeats for post quantum cryptography, he cannot say, but Infineon is preparing for either outcome. Germany’s Employee Invention Act: opportunity or burden Asked whether Germany’s Employee Invention Act is an opportunity or a burden for the country’s innovation ecosystem, Berg does not hold back. With more than 30 years of experience, he estimates that 99 percent of all inventions are simply the regular work product of engineers in R&D, requiring no extra incentive at all. In countries without an equivalent law, employees are demonstrably just as innovative and just as willing to share their inventions with the company. His core objection is that invention does not equal innovation. Procurement, production, quality management and many other functions all contribute to a product’s success, not just the named inventors. That the inventor alone receives extra compensation while everyone else does not strikes Berg as unfair, especially since Infineon already rewards its top engineers appropriately regardless of statutory requirements. He calls the law a bureaucratic nightmare that should be abolished or at least radically simplified. Smaller organizations, he notes, often just ignore it or implement it badly, and every company Infineon has acquired with German operations has come with its own legacy mess to clean up. Artificial intelligence in day to day patent work at Infineon On AI, Berg describes three layers. The first is established tools: patent search, translation between the team’s main working languages, and, for about two years now, drafting replies to office actions. As with any tool, the benefit only shows up with repeated use at real volume, which is why Infineon works deliberately with outside counsel to broaden adoption across the team. The second layer is ongoing testing of new tools, limited mainly by the time available to evaluate them. The third is everyday office use. Since spring 2025, everyone from paralegals to attorneys has been able to use AI tools broadly within a secure environment. The bar stays the same throughout: if AI output is not at least as good as an attorney’s prior work, it is not worth using, or the cleanup afterward eats up any time saved. Where it does work, responses to standardization proposals, for instance, can be produced far faster. One question Berg expects to face next year, without yet having an answer: how should efficiency gains be split between the company and outside counsel once both sides benefit from AI? Three messages for the IP community I closed by asking Berg for the most important messages he would want to give our listeners, mostly IP professionals in companies and law firms. His first message: think about IP strategy from the end, starting with what needs to be asserted against whom and for what purpose in ten or twenty years, rather than letting today’s deadlines dictate everything. Only that kind of multi year plan, combined with a sound cost benefit ratio, produces genuinely litigation ready patents. His second message is again about artificial intelligence: anyone who has not started training with it yet risks missing the wave, and this is not a skill built overnight. His third message is aimed at anyone not yet connected to peers in the profession: use the associations and networks that already exist to build that exchange, a thought that ties neatly back to the VPP, where our conversation began. And here is the full transcript: Peter Berg: Hi, I’m Peter Berg, Chief IP Counsel at Infineon Technologies and President of VPP, the Association of In-house Patent Practitioners in Germany. And you are listening to IP Fridays. Rolf Claessen: Today’s interview guest is Peter Berg. If you don’t know Peter, he is an electrical engineer by training and is the Chief IP Counsel at Infineon Technologies and also serving as the VPP president. Thank you very much for being on IP Fridays. Peter Berg: My pleasure. Rolf Claessen: So first I want to talk about VPP. You succeeded Beat Weibel from Siemens as VPP president in May 2024 and have publicly called for Germany to finally deliver on the coalition agreement promise of the national IP strategy. So politics, what are the two or three most concrete things that strategy must contain? What happens if it doesn’t get done in this legislative period? Peter Berg: First of all, I think I need to correct you. It was May 2025, so not that long as a standing president. But if you mention national IP strategy, national means here for Germany. I think the question isn’t anymore whether or what happens if we don’t get that strategy. I think that is now on its way. The question is rather how good and comprehensive the national IP strategy will be, and if it’s just not enough from an industry perspective, I would say then we adjust afterwards. Of course, there is a big paper out from the BDI, the German Industry Association, published in 2024, and I need to focus on something which is really close to my heart. If you ask me the main content it should have, it is first of all better IP education, and I see there are kind of three levels. One is really society as such, so each and everybody from kindergarten to retirees, we need to acknowledge in the knowledge society that IP is central for our well-being. We have to respect the IP of others. We have to be proud to create IP, not just treat it as an entry in the accounts. Yeah, society at large. The second level is really academia and education in our professional environment. And finally, life is difficult for startups, people who want to create a new company, and small and medium-sized enterprises. There is good stuff out there. The German Patent and Trademark Office has a mandate to educate, but a very small budget to do so. In a federal country like Germany, there are local support systems, be it the chambers of commerce or the patent information centers. The structure is there, but it’s underfinanced, and Germany has to gear up on that one. So besides IP education, I believe solid national IP institutions are key. This is also a funding issue, be it headcount or technology. Think of the German Patent and Trademark Office, think of the courts, be it on the infringement side or the nullity side, so the Federal Patent Court. We need to back up nationally the European institutions, since we believe not every case is worth taking to the UPC, so for smaller cases we need a good national system as a backup. And government needs to have that in mind and not rely too much on European institutions alone. Finally, facilitate the IP transfer from universities and research institutions into industry. Right now it’s all about startups, et cetera, but that kind of IP transfer starts first of all with people leaving university, leaving those research institutions and joining industry, be it as staff or through research contracts. And finally, of course, startups are the area where Germany needs to catch up in particular. Perhaps I need to add for non-German listeners, there is a particularity in Germany in that the IP institutions, like the Patent and Trademark Office, report into the Ministry of Justice, although it’s an instrument for thriving innovation and building a solid economy. So it’s right now a totally new thing for this country that three ministries, research, economy and justice, are working together on this national IP strategy, with only recently some good progress. Rolf Claessen: You’ve said publicly that Infineon’s primary focus is patents that provide clear competitive advantages, and that for you it’s about litigation-ready patents. That’s a very specific phrase. How do you define it operationally, and how has the pruning of your more than 12,000-family portfolio changed in the last two years? Peter Berg: Yeah, I think that’s a process which lasted much more than two years, and it’s never over. This is work in progress. Thinking back to 2017, I joined Infineon, and the company has developed very nicely since. I think we roughly tripled turnover but kept the portfolio size roughly stable, despite acquisitions, despite that growth, also in R&D, et cetera. We’ve even been able to shrink costs since then, and I believe we’ve achieved our strategic goals, now with a good, or let’s say not yet good enough, cost-benefit ratio. And the answer to that equation is quality. Now, we as patent practitioners might call it differently, but at the end it comes down to the fact that, most likely for all companies and for practitioners who support companies in private practice, you need a collaboration platform. That means for Infineon, the inventors are key. They are involved in decision-making, so they pitch their invention to senior technical experts, my team members, and patent attorneys, and the quality of that expert panel makes a big difference. Then come repetitive reviews, not just once the decision to file is taken, but the draft itself is also reviewed by multiple stakeholders. Then we get the notice of allowance, the patent is granted, another review, and later on we try to apply consistent criteria: what’s the technology assessment, what’s the market size, is it detectable, is it easy to circumvent, et cetera, and does it fit with our own roadmap. And of course it would be nice if you could easily compare it with a competitor’s roadmap, or take the time to speculate on certain market changes which might be disruptive. And I believe if you apply that consistently over a sufficiently long period, you get patents you could call litigation-grade or litigation-ready. What is then missing, though, is real experience with conflicts against competitors and how the courts look at that. So the truth comes out once you go to court. On the defensive side, of course, we have tons of experience trying to find weaknesses in patents being asserted against Infineon, et cetera. But I think it’s another level of learning to be on the offensive, and that might play out in court, but it might also play out in licensing negotiations, where the other side is sufficiently unsure whether they would get an outcome they believe would be fair if they went to court with those patents. You asked me about the pruning of all this. So what is our approach there? There is a kind of forced pruning rate which we believe is necessary, to make it mandatory for everybody to identify the weakest patents in the respective portfolios. We focus on the years where costs are highest, what we internally call US8 and US12, since a big chunk of money needs to be spent on annuity payments for the US portfolio, which is the dominant one, and for the rest of the world it’s rather towards the end of the patents’ lifecycle. Now, having a good team, people who really like the technology and stay in charge for a long time, I could proudly say that my team knows every one of those 12,000 patent families well, and not just on the German or the US side, but really focuses on the jurisdictions with the biggest markets for electronic products. And there we see offensive litigation as a good choice, and that is Germany, the US and China. Rolf Claessen: Yes, talking about patent quality is really a hot topic right now, especially in industry and at the EPO, I guess, but that’s a topic for a different hour, probably. But talking about litigation-ready patents, you recently obtained possibly the first ex parte preliminary injunction at a German trade show in recent history, without a protective writ having been filed by the defendant. What does that show about your view on German national courts versus the UPC for this kind of enforcement? Peter Berg: I mean, first of all, litigation is not an end in itself, and in the markets a semiconductor company like Infineon operates in, a product might implement potentially hundreds or thousands of patents. So litigation itself doesn’t resolve all of that, but it has its place in our strategy execution. You’ll understand that I can’t get into specifics of any of the litigations you hinted at. But enforcement of trademarks, and I think you mentioned a patent case, trademarks and patents at trade fairs has been part of our activities for years, and sometimes you can catch somebody by surprise. It’s all about good preparation. But what I believe is more important is that we also prepare for venues so far less used by Western companies, be it China, et cetera. So being litigation-ready means looking into different venues. The UPC is certainly one of them, but there’s more beyond that. Enforcement for us is not only a German or European measure. I personally believe national courts and the UPC will both have a role to play in the future. There are pros and cons to each, which need to be evaluated case by case. I need to congratulate the UPC, which had a great start, good management, good communication about what they do, and a selection of judges based on quality, not politics. In a little more than three years, they’ve built up a pretty good body of case law. On the downside, some countries are still missing, building a really comprehensive body of case law will take time, and the cost side is still a concern, meaning that not every kind of business case reaches damages high enough to justify it, and there’s a certain risk that the case won’t be decided quickly by the court. In such situations, it might not make sense to go to the UPC. We have, I guess, quite a few companies in the electronics or mechanical engineering field where we don’t validate European patents in dozens of countries, maybe two, three, four, and over time it might be even fewer. So geographically, the difference between US, UPC and national enforcement isn’t that big. That’s why the alternative, and I mentioned this a bit at the beginning regarding the national IP strategy, needs to stay a good alternative. So the possibility to opt out and litigate nationally in lesser business cases remains, from my perspective, important, and we continue to use that as well. Rolf Claessen: Yes, and also the hurdle for double patenting has been lowered a little, so you can still have national patent rights in parallel with UPC patent rights. That’s also an advantage, probably. Peter Berg: Yeah, I think that was almost an invitation to say, you know, if you’re not sure whether the unitary patent is your choice, you can do both in parallel. True. But again, all we need to do is achieve our goals with a good cost-benefit ratio, so systematically double patenting is not really the way forward for us. Rolf Claessen: Right. Yeah, that was a very interesting insight about German national courts versus the UPC. But in fact you’re also litigating across borders, in many different countries, for example the US, Europe, Germany, and other countries, in China maybe. So what does coordinating enforcement across all these different systems simultaneously actually look like from the inside, and was it always the plan to have such complex litigation and enforcement systems, or did it evolve? What’s your take on this? Peter Berg: Yeah, at Infineon, our legal and patent departments, as we call them, have grown together over the last 25 years, roughly the age of our company, into an organization that doesn’t just have broad general legal or semiconductor application market expertise, for us that’s automotive, consumer goods, industrial and IoT, but is an organization that’s been tested by hundreds of assertions against us and our customers, and by negotiations with operating companies and NPEs. So that comes with experience. If I look now at our organization, not just my own team but legal in general, we have patent and legal teams in all the hotspots, and that’s grown in the last couple of years too. It’s Europe, of course North America, and various countries in Asia, and it’s a fully integrated international organization. We know each other and communicate, it feels like, on at least a weekly basis. Not to forget a good network of outside counsel to execute enforcement wherever strategic needs require it. That’s kind of our promise to management: we don’t shy away from any jurisdiction, if the need is there we can act and set up a team. Perhaps we’ve learned more on the defensive side, which we can now translate into offensive action. And I guess you’re somehow relating your question to a specific litigation against a Chinese competitor, and that’s not a litigation you kind of slide into. You need to plan a few steps ahead. Litigation has become part of our daily life, and the key moment is always, once it’s decided that this is going to happen, to set up a team for the new litigation. It starts to feel like a routine operation. The staffing depends of course on the technical area of the enforcement, the jurisdiction, and the workload of existing attorneys. And the good thing is that once we rotate patent attorneys into a litigation team, it’s great experience for them, that leads to expertise, and since we try not to over-specialize, so that people don’t only do litigation or only do prosecution, that experience from litigation is a great asset when they go back to supporting a certain business unit doing prosecution work. And coming back to your first question, that personal experience also helps in creating litigation-ready patents over time. Rolf Claessen: Yes, you’ve also acquired a couple of companies, and I have a question about a certain deal, especially the Marvell Brightlane acquisition and the IP due diligence. This $2.5 billion Brightlane deal closed in August 2025 and presumably transferred a substantial patent portfolio in the automotive, let’s say networking, technology field. How much of that big deal is really about buying IP, and how does a deal like that change your daily work in your IP function the day after closing? So once you’d signed the deal, did your daily life change? Peter Berg: It depends on the size of the deal. A couple of questions in there. Let me start with IP in the semiconductor industry, my industry, and that’s more than patents, trademarks and design rights. Speaking to practitioners and R&D colleagues, IP for them is rather frozen technologies and what we call IP blocks, design blocks which enable fast product designs that you can reuse. And if I take that as a basis, although each acquisition is different, IP plays a very big role because it should enable us to bring new products to market quickly, et cetera. Seldom does Infineon acquire a business because of its patent portfolio. Being a large, established player, our existing patent portfolio should be good enough to move into whatever technical area is of interest, and to make sure incumbent competitors couldn’t easily attack us when entering that field. Now, you mentioned the Marvell acquisition. We call it rather the Marvell automotive Ethernet acquisition. From Marvell’s perspective it was a smaller part of their business, which they sold to Infineon about a year ago. How should I say it, you get the assets but you get relatively little IP. So it’s more that you try to familiarize yourself with the assets and how they fit our business case, et cetera. Of course there is due diligence to get an idea and to make sure that everything that should belong to the business is transparent, but the more important part comes after the acquisition. Once the business is owned by Infineon, all the other functions handle their own areas of responsibility. For us, when it comes to IP rights, it’s about reaching out to the new colleagues, helping them for the first couple of days, but also leaving them alone, because there are so many changes they have to go through, and not being overly pushy. Understanding their current processes and tools, and their view of their own portfolio, is important at that point. So you hold back a little and see what they do and why they do it, sometimes you can learn from their best practices. But there comes a moment when we need to finally decide how to integrate the portfolio, and which of our processes and tools they have to adopt, and the faster you make that decision, the better. Since in the case of Marvell none of the IP staff joined us, the task was to build up a portfolio using the expertise of the senior engineers, get a good operational patent committee running, and develop a plan for which areas of the portfolio are good enough and which need to grow, in line with the growth of the business. It’s now more than a year ago, but that was an interesting time, and I doubt many people listening are aware of it, but a big thank you to everybody involved back in 2025. Rolf Claessen: From your answer I get that your job involved a lot of listening, basically, to the needs of the teams that joined your company, right? Peter Berg: At least as much talking as listening. Of course they want to know as well how we do things and what’s expected of them. So first of all it’s about reaching those people and making sure, and this is also a concern, that if everything changes for them, then perhaps the patenting process isn’t the most important thing. Product development is key, and making sure there’s no interruption so they can keep their timelines, et cetera. So being very mindful of that setting. But you’re right, it’s not just about telling them, it’s about listening to them and finding the right moment to switch. Rolf Claessen: Right, I have a very different question now, about NPEs, non-practicing entities, and exposure. I think some NPEs acquired patent families that trace back to Cypress, just before you bought it, or around the time of your acquisition. Are these patents, held by these NPEs, now a problem for Infineon? Peter Berg: That would be it, right? Actually, no, let me give some context first. Companies in distress, or with an overly large patent portfolio for their business, sometimes sell patents at a certain point in their history. Regarding Cypress Semiconductor, that happened around 2016, after they merged with a company called Spansion and ended up with a large combined portfolio they didn’t need. At that point Cypress teamed up with an NPE organization called IP Value and sold them around 2,000 patents, that’s public knowledge, and only a few years later Infineon acquired Cypress. So that was done by Cypress before it became an Infineon company. But good practice is, if you sell a patent, you retain a license for your own business, so in that sense I don’t feel any exposure from those patents. But of course this touches on the general topic of exposure to NPE enforcement, which is a concern in the electronics industry. Realistically, hundreds is perhaps too much, but many dozens of new cases a month, often against our customers or the wider ecosystem. But since it involves technology implemented in our products, even if the enforcement doesn’t target semiconductor players directly, we need to support our customers, and that is a kind of a load we need to help carry. But these are typically patents that somebody else sold to an NPE. You were also asking whether acquiring businesses brings new opportunities as well as new risk. I think that’s natural, and we shouldn’t shy away from that kind of risk. If we, like any other company, go for the big, high-margin, fast-growing businesses, the stakes are high in those areas, and you can’t complain if these also turn out to be litigious marketplaces, because many people want to be there. Around this time of year, since it’s Oktoberfest season here in Munich, many IP practitioners from around the world gather for meetings and share their view on the world. Everybody talks about AI, and NPEs try to acquire whatever patents are on the market that could be the basis of stronger or weaker infringement actions against that part of the industry. From an industry perspective, this consumes a lot of resources and doesn’t really help accelerate innovation in our space. Rolf Claessen: Good that you have a solution for the patent families that were acquired before you acquired Cypress. And now, turning to a very different topic, cryptography. You’re also working on quantum cryptography and post-quantum cryptography, a difficult word, and you, Infineon, were the first to obtain a certification, a really high certification in post-quantum cryptography, the so-called CC EAL6 certification, a very high certification in cryptography for our listeners, in December 2024. Now this field of technology is heading towards standardization. How patent-dense is Infineon’s patent stack in this field, and how are you thinking about the potential standard-essentiality of this new post-quantum cryptography technology, where maybe the American standards from the NIST institute become the infrastructure, or the standard? Peter Berg: It’s a big field with different components. We take the quantum challenge seriously at Infineon, but there are two elements to it. You spoke more about cryptography, but for us, as a semiconductor player, on one hand we want to enable quantum computing with our own chipsets, and we support two different technology streams there, it’s not just development, it’s already a real business. On the other hand, we need to educate and enable customers in the application fields we serve to prepare for that quantum day, the day quantum computing becomes available, and not only to the good guys. You need to think about this now, because it might be just three, four, five years away, you don’t know for sure. It means investing in infrastructure able to handle post-quantum cryptography and security in communications, because you need certain computing power and different ways of handling cryptography algorithms compared to today. Today’s approaches won’t be enough, you need better ones, and you mentioned one at the beginning, which Infineon has proposed. That’s not easy. If you invest in a core today, you’re investing in something like a power station, which stays connected to the internet for a long time, so you need infrastructure robust enough to handle post-quantum cryptography. Regarding the patent stack question, yes, certainly there are several patents in this field owned by Infineon, but also by others. In general, I believe, both in semiconductors and in security more broadly, this tends toward royalty-free licensing, and standard setting has in the past been marked by the avoidance of the big patent clusters we saw building up in cellular communication, from 2G through 5G. I don’t see that happening in the post-quantum cryptography field, but who knows, so we prepare for whatever scenario comes. Rolf Claessen: Let’s see if the Infineon patents end up in a big pool or something later on, and you get all these license fees. Peter Berg: I wouldn’t mind, yeah. Rolf Claessen: Let’s see. Right, now turning to another topic, maybe, for example US colleagues ask me a lot about the German employee invention law. It’s very different from other countries, especially the US. Do you see the German employee invention law rather as an opportunity or a burden for Germany’s innovation ecosystem? Peter Berg: As IP professionals in larger corporations in Germany, we’re so used to that law that we hardly challenge its usefulness. To your question, though, with more than 30 years of experience, I’d say that 99% of all inventions are made by engineers in R&D as part of their regular job, nothing extra on top, so they don’t need an extra motivation for it. And we see it in other countries too, where that kind of law doesn’t exist, and people are just as innovative and just as ready to share their inventions with us as an IP organization, with or without the law. So it doesn’t seem to fulfill the role some see as a competitive edge for Germany, and because of that inventor law, people just end up being more cautious, or more descriptive, about their work results. There are more reasons why I believe this is obsolete. Invention does not equal innovation. There are many other colleagues in a company, in procurement, production, quality management, et cetera, and all of them contribute to a product becoming a bestseller. It’s not a single person, and it’s not just one team’s result, and somehow it doesn’t feel fair that the inventor gets an additional bonus and the others don’t. In any case we’d give our top engineers a premium anyway, and we reward inventors in all other countries, with the law or without it, without any worldwide mandate for that kind of remuneration. So from a corporate perspective we don’t need a law to help us work out the benefits and share them with our top inventors. The law is a bureaucratic nightmare. It needs to be abandoned, or at least radically simplified. In smaller organizations, I guess it’s often just ignored or badly implemented. Believe me, every company we’ve acquired with operations in Germany has left us a bit of a heritage to clean up. Rolf Claessen: Yeah, I understand. Now for a different topic, AI, the use of AI. We as patent attorneys talk about this a lot, it’s a big topic, how to use AI, whether to use AI, and how to use AI in law firms. But can you tell us about the use of AI in the operations of your team? Peter Berg: Recently we discussed this and agreed on kind of three layers to it. First, good use of established AI tools. AI, in that sense, isn’t something that started three years ago with ChatGPT. It began with search, patent search, then translation, at least between the major languages like German and English, which most of my team masters, and then, I’d say about two years ago, drafting and replies to office actions. So there are established tools, and as with every tool, you need to use it repeatedly, at a certain volume, to really benefit from it. We try to work with the best of these established tools, driving wider adoption within the team and partnering with our law firms, since a substantial part of the legal work is done by our outside counsel. So this is a bit of a joint exercise. Second, there are constantly new tools coming up, which we try to test. There are many, so the time we have available to look into them is the limiting factor. I’d like to test more, because there might be a new frontrunner coming up that we should definitely try ourselves. But last, and certainly not least, we try to implement AI into everyday operations, into the office environment itself. The company made a good decision in spring to allow wide adoption of AI-specific tools in a secure environment, and that has opened up a lot of opportunities for everybody, paralegals and attorneys alike, and now it’s about fostering an open exchange on what’s possible and what’s not. And finally, since Infineon, like most corporations, doesn’t do everything in-house, there’s the question of what the benefits are that we can plan around, so that we get better quality. If the quality of the AI results isn’t as good as the attorney’s results before, then we shouldn’t use it, or we’d spend so much time cleaning it up afterwards that nobody could tell the difference. Second, we can now do things that weren’t possible before, because they were too tedious or took too long, or we get faster turnaround times, so we can respond more quickly to standardization proposals, what used to take many days we can now do in a few days, while still trusting the quality of the output. And only then comes what’s often discussed as efficiency gains, and the question that will probably be asked next year is how we split the pie: if both we and outside counsel benefit from using AI, what do we do with those benefits, how much stays with outside counsel, and how much should also benefit my budget? Rolf Claessen: But I clearly see the advantages of using AI, I’m using it myself, especially for cases like oppositions, where in earlier times you had to read through some 30 papers, patents and books, and now you can just ask the AI where you find a certain feature across those 30 documents. So it’s really useful in a lot of cases. Now my last question to you, and maybe the most important one, what do you think are the three most important messages you want to convey to our listeners, who are mostly IP professionals, both in-house and in law firms? Peter Berg: Do you want me to repeat things I said before, or can I think freely, in general? Free thinking, of course. Okay. Many of the things we spoke about now were about what to do next, and how to execute certain things, how to prepare. I believe that if you think about IP strategy, you think about it from the end: what do I need to assert, against whom, for what purpose, before building a portfolio of IP rights. So it’s not just about the deadlines you have today and tomorrow, which you somehow have to get through, but about taking a step back and thinking, what should this be good for in 10 or 20 years’ time. If you do that, it helps you get to litigation-grade patents and litigation readiness. We’re all busy, and there are so many things we need to do today and tomorrow, so it’s easily forgotten to look a little further down the road. So I’d say, think about a multi-year plan to achieve your goals, and there are hardly any moments, unless perhaps you’re one of the big AI platforms with unlimited resources, where that isn’t true. So plan for multiple years, but with a good cost-benefit ratio in mind. And I can’t really avoid mentioning AI here. It’s having a major impact on our operations. We’ve talked about it, we’ve tested it, but ramping it up is a different matter, and I think next year will be decisive. That’s really the full value chain, from interacting with our inventors to get better quality ideas, all the way to claim charting and negotiating, the bread-and-butter activities of patent attorneys, drafting office action replies is of course part of that too. I’m really keen to see that happen, and I’m trying to keep my team ahead of the wave. And I can only encourage everybody in our profession, if you don’t yet have a contact, team up with friends or colleagues in the profession, use the various associations that exist in our profession to network and discuss. The worst thing is to miss the train, and it takes time, this isn’t something you become good at overnight, so it needs time to train, and it’s good to start now. Rolf Claessen: Yes, that’s a very good point, and closing where we began, with the VPP, exchanging ideas among colleagues really is key, I think, important. Thank you very much for being on IP Fridays, on our podcast. That was really interesting, and I think our listeners can learn a lot from this interview. Thank you very much. Peter Berg: Don’t mention it, it was a pleasure talking to you, and for me it was also the first time doing this kind of podcast. Thank you. Rolf Claessen: Thank you

Frankie Val goes solo for a self described grab bag night, just him and what he calls the molten core of his audience. He opens on Rumble landing WWE Main Event and turns it into a lament for what social media used to be, back when authenticity and consistency beat paying to boost a post into an algorithm that no longer serves the creators who built real bonds. From there it wanders happily. A viral South Korean dating show about human AI romance (Frankie is unimpressed, noting people have loved inanimate objects forever), his blunt disgust at the mRNA fast tracking victory laps out of the UN week, and Iran's threats against the undersea cables that carry the Internet. The back half leans personal and strange, built around dreams, false memories, and a dream story of his own, plus a collection of audience submitted reels and the never ending Mitch McConnell updates. Five Super Chat raffle winners get picked.

Join the Conversation at 303-477-5600 or text 307-200-8222. Monday-Friday, 3 p.m.- 6 p.m. MT. https://RushToReason.com HOUR 1 The Drugstore Double Standard: Ivermectin, Kratom & Gas Station Heroin. Prepare to question everything you thought you knew about health. John Rush, Dr. Kelly Victory, and Steve House ignite a bold debate on medical freedom, controversial COVID treatments, and the secrets big pharma doesn't want you to hear. Discover Dr. Victory's behind-the-scenes push to pull mRNA products off the market—will political pressure finally break through? Dive into the hot-button controversies of vaccine safety, emerging mRNA cancer breakthroughs, and the surprising cancer-fighting potential of common medications like ivermectin. Unlock the real secrets to staying strong, energized, and independent as you age—don't miss this eye-opening discussion. Think nothing could shock you? Wait until John exposes the dangers of ‘gas station heroin' and kratom—why are these risky substances for sale on every corner while life-saving meds are locked behind the counter? From vitamin D to dangerous supplements, this hour smashes health myths and challenges you to rethink your wellness choices. Guests 01:08 — Dr. Kelly Victory — https://www.twc.health/ 01:08 — Steve House HOUR 2 Water Wars: Is Colorado's New Law Making Affordable Housing Impossible? Could Colorado's Mobile Home Water Quality Act spell disaster for affordable housing? John Rush and Paul from WaterPros pull back the curtain on costly water regulations, steep penalties, and the real impact on families. Find out what's at stake, and who is really paying the price. Then, Amy Oliver Cooke joins John to dissect the high-stakes 8th Congressional District race where energy policy, jobs, and the future of Weld County hang in the balance. Get the inside scoop on how oil, gas, and agriculture could sway the outcome. With Election Day looming, John unpacks rifts inside Colorado's Republican party, Greg Lopez's outsider campaign, and the fierce battles for voter attention that could decide the state's future. Guests 01:11 — Paul, WaterPros — https://os.net/ 26face in buildingmy Oliver Cooke — https://www.aoenergy.org/ HOUR 3 AI Takeover, Exploding School Costs & the Political Race You Can't Afford to Ignore John Rush and Jerzee Joe go deep on the AI revolution—will your job be next? Find out how automation is shaking up fast food, why school budgets are exploding, and which states are struggling to keep education spending in check. This hour is packed with eye-opening facts and tough questions about your wallet and your future. Think you know what's driving up your costs? Discover the hidden forces behind pricier oil changes and ballooning Medicaid expenses that are hitting Colorado's budget—and your bank account. RNC's Zach Kraft breaks down the high-drama 8th District race, untangles election rules, and reveals what's really at stake for Colorado's energy future. John wraps up with a look at Victor Marx's bold campaign prayer initiative, then takes you inside the heated debates on Wyoming's elections, property taxes, and the fight for transparency in schools. 01:08 — Jerzee Joe — https://jerzeejoe.com 25:37 — Zach Kraft — https://www.gop.com

Join the Conversation at 303-477-5600 or text 307-200-8222. Monday-Friday, 3 p.m.- 6 p.m. MT. https://RushToReason.com HOUR 1 The Drugstore Double Standard: Ivermectin, Kratom & Gas Station Heroin. Prepare to question everything you thought you knew about health. John Rush, Dr. Kelly Victory, and Steve House ignite a bold debate on medical freedom, controversial COVID treatments, and the secrets big pharma doesn't want you to hear. Discover Dr. Victory's behind-the-scenes push to pull mRNA products off the market—will political pressure finally break through? Dive into the hot-button controversies of vaccine safety, emerging mRNA cancer breakthroughs, and the surprising cancer-fighting potential of common medications like ivermectin. Unlock the real secrets to staying strong, energized, and independent as you age—don't miss this eye-opening discussion. Think nothing could shock you? Wait until John exposes the dangers of ‘gas station heroin' and kratom—why are these risky substances for sale on every corner while life-saving meds are locked behind the counter? From vitamin D to dangerous supplements, this hour smashes health myths and challenges you to rethink your wellness choices. Guests 01:08 — Dr. Kelly Victory — https://www.twc.health/ 01:08 — Steve House HOUR 2 Water Wars: Is Colorado's New Law Making Affordable Housing Impossible? Could Colorado's Mobile Home Water Quality Act spell disaster for affordable housing? John Rush and Paul from WaterPros pull back the curtain on costly water regulations, steep penalties, and the real impact on families. Find out what's at stake, and who is really paying the price. Then, Amy Oliver Cooke joins John to dissect the high-stakes 8th Congressional District race where energy policy, jobs, and the future of Weld County hang in the balance. Get the inside scoop on how oil, gas, and agriculture could sway the outcome. With Election Day looming, John unpacks rifts inside Colorado's Republican party, Greg Lopez's outsider campaign, and the fierce battles for voter attention that could decide the state's future. Guests 01:11 — Paul, WaterPros — https://os.net/ 26face in buildingmy Oliver Cooke — https://www.aoenergy.org/ HOUR 3 AI Takeover, Exploding School Costs & the Political Race You Can't Afford to Ignore John Rush and Jerzee Joe go deep on the AI revolution—will your job be next? Find out how automation is shaking up fast food, why school budgets are exploding, and which states are struggling to keep education spending in check. This hour is packed with eye-opening facts and tough questions about your wallet and your future. Think you know what's driving up your costs? Discover the hidden forces behind pricier oil changes and ballooning Medicaid expenses that are hitting Colorado's budget—and your bank account. RNC's Zach Kraft breaks down the high-drama 8th District race, untangles election rules, and reveals what's really at stake for Colorado's energy future. John wraps up with a look at Victor Marx's bold campaign prayer initiative, then takes you inside the heated debates on Wyoming's elections, property taxes, and the fight for transparency in schools. 01:08 — Jerzee Joe — https://jerzeejoe.com 25:37 — Zach Kraft — https://www.gop.com

Join the Conversation at 303-477-5600 or text 307-200-8222. Monday-Friday, 3 p.m.- 6 p.m. MT. https://RushToReason.com HOUR 1 The Drugstore Double Standard: Ivermectin, Kratom & Gas Station Heroin. Prepare to question everything you thought you knew about health. John Rush, Dr. Kelly Victory, and Steve House ignite a bold debate on medical freedom, controversial COVID treatments, and the secrets big pharma doesn't want you to hear. Discover Dr. Victory's behind-the-scenes push to pull mRNA products off the market—will political pressure finally break through? Dive into the hot-button controversies of vaccine safety, emerging mRNA cancer breakthroughs, and the surprising cancer-fighting potential of common medications like ivermectin. Unlock the real secrets to staying strong, energized, and independent as you age—don't miss this eye-opening discussion. Think nothing could shock you? Wait until John exposes the dangers of ‘gas station heroin' and kratom—why are these risky substances for sale on every corner while life-saving meds are locked behind the counter? From vitamin D to dangerous supplements, this hour smashes health myths and challenges you to rethink your wellness choices. Guests 01:08 — Dr. Kelly Victory — https://www.twc.health/ 01:08 — Steve House HOUR 2 Water Wars: Is Colorado's New Law Making Affordable Housing Impossible? Could Colorado's Mobile Home Water Quality Act spell disaster for affordable housing? John Rush and Paul from WaterPros pull back the curtain on costly water regulations, steep penalties, and the real impact on families. Find out what's at stake, and who is really paying the price. Then, Amy Oliver Cooke joins John to dissect the high-stakes 8th Congressional District race where energy policy, jobs, and the future of Weld County hang in the balance. Get the inside scoop on how oil, gas, and agriculture could sway the outcome. With Election Day looming, John unpacks rifts inside Colorado's Republican party, Greg Lopez's outsider campaign, and the fierce battles for voter attention that could decide the state's future. Guests 01:11 — Paul, WaterPros — https://os.net/ 26face in buildingmy Oliver Cooke — https://www.aoenergy.org/ HOUR 3 AI Takeover, Exploding School Costs & the Political Race You Can't Afford to Ignore John Rush and Jerzee Joe go deep on the AI revolution—will your job be next? Find out how automation is shaking up fast food, why school budgets are exploding, and which states are struggling to keep education spending in check. This hour is packed with eye-opening facts and tough questions about your wallet and your future. Think you know what's driving up your costs? Discover the hidden forces behind pricier oil changes and ballooning Medicaid expenses that are hitting Colorado's budget—and your bank account. RNC's Zach Kraft breaks down the high-drama 8th District race, untangles election rules, and reveals what's really at stake for Colorado's energy future. John wraps up with a look at Victor Marx's bold campaign prayer initiative, then takes you inside the heated debates on Wyoming's elections, property taxes, and the fight for transparency in schools. 01:08 — Jerzee Joe — https://jerzeejoe.com 25:37 — Zach Kraft — https://www.gop.com

English being the common language in scientific research has its pros and cons. Scientists can collaborate easier and research can become more accessible, but what do we lose in that process? And what role does AI play? To discuss the complexities of scientific translation, Dr. Samantha Yammine is joined by Dr. Lynn Bowker. Dr. Bowker is a Canada Research Chair in Translation, Technologies, and Society at Université Laval. Sam also explores how a new mRNA vaccine is using AI to keep skin cancer from reccuring and a study measuring how guilty people feel when they're relaxing. Link to Show Notes HERE Follow Curiosity Weekly on your favorite podcast app to get smarter with Dr. Samantha Yammine — for free! Still curious? Get science shows, nature documentaries, and more real-life entertainment on discovery+! Go to https://discoveryplus.com/curiosity to start your 7-day free trial. Terms apply. Hosted on Acast. See acast.com/privacy for more information.

Energy prices, Canadian politics, propaganda tactics, and a stack of culture-war clips. It matters because the discussion keeps circling back to how narratives are built, repeated, and used to shape public belief around diesel, climate, medicine, and government power. We discuss Canadian and U.S. energy dependence, media framing, and a series of examples Darren and Graham use to argue that institutions are manufacturing consent through repetition, selective coverage, and bureaucratic theater. Key topics In this episode: Graham talks about working the fields and how combine harvesting demands constant attention because equipment clogs and you cannot just cruise through it. Darren and Graham compare weather, harvest timing, and the practical costs of heat, diesel, and natural gas in late season. They discuss the idea of a U.S. diesel export ban and what that could mean for Canada, especially Ontario, Saskatchewan, and eastern pricing. Graham argues that global energy pricing is heavily interconnected and politically managed rather than purely market-driven. They react to a clip about Marc Carney and describe his communication style as a repeated use of the same phrases, especially "deepening," which they frame as a propaganda tactic. Darren plays through examples of Canadian political and media messaging, including climate language, aid to Ukraine, and claims about national decline. They discuss a Toronto school board example that frames stoicism, self-sufficiency, mental toughness, and physical toughness as toxic masculinity traits. Darren and Graham critique a viral clip about MAID and the Canadian medical system, then pivot into broader concerns about healthcare delays and treatment windows. They dig into "illusory truth" as a persuasion strategy, where repetition makes claims feel believable even when the underlying facts are weak. Later segments move into broader historical and philosophical quotes from Hannah Arendt and Ayn Rand about corruption, social collapse, and belief manipulation. The back half shifts into infrastructure failure, including a Los Angeles bridge project Darren cites as an example of waste and decay. The episode closes with a long exchange about vaccines, mRNA, tick-borne illness claims, the PREP Act, and mistrust of public health institutions.   To gain access to the second half of show and our Plus feed for audio and podcast please clink the link http://www.grimericaoutlawed.ca/support. For second half of video (when applicable and audio) go to our Substack and Subscribe. https://grimericaoutlawed.substack.com/ or to our Locals  https://grimericaoutlawed.locals.com/ or Patreon https://www.patreon.com/grimericaoutlawed   https://www.skool.com/audiobooks THE GRIMOIRE Audiobook Club and Library https://pegsandjokers.ca/ Family and Friends Cards and Pegs Boardgame online https://www.simulationmaps.com/#products Disaster Maps, Volcano Sim, Asteroid Sim, Shipwreck Map, UFO Map etc Support the show directly: https://open.spotify.com/show/2punSyd9Cw76ZtvHxMKenI?si=ImKxfMHgQZ-oshl499O4dQ&nd=1&dlsi=4c25fa9c78674de3 Watch or Listen on Spotify https://grimerica.ca/support-2/ Our Adultbrain Audiobook Podcast and Website: www.adultbrain.ca Check out our next trip/conference/meetup - Contact at the Cabin www.contactatthecabin.com Join the chat / hangout with a bunch of fellow Grimericans Https://t.me.grimerica grimerica.ca/chats   Discord Chats Darren's books www.acanadianshame.ca Sign up for our newsletter http://www.grimerica.ca/news InstaGRAM https://www.instagram.com/the_grimerica_show_podcast/ Purchase swag, with partial proceeds donated to the show www.grimerica.ca/swag ART - Napolean Duheme's site http://www.lostbreadcomic.com/ MUSIC Tru Northperception, Felix's Site sirfelix.bandcamp.com Links to the stuff we chatted about: https://x.com/ProtesterLone/status/2102410589553455553?s=20 https://x.com/ryangerritsen/status/2102099429452865996?s=20 https://x.com/McMichelSim/status/2101738255112638730?s=20 https://x.com/TheBuckYouWill/status/2100732784931479717?s=20 https://x.com/ryangerritsen/status/2100628848618467485?s=20 https://x.com/JonMajerowski/status/2100282844153082369?s=20 https://x.com/HighersideChats/status/2097313930456531375?s=20 https://x.com/WallStreetApes/status/2096618172933652683?s=20 https://x.com/NakedHedgie/status/2091105130640720328?s=20 https://x.com/AshtonForbes/status/2099521051726115199?s=20 https://naomiwolf.substack.com/p/dr-mccullough-releases-study-linking?utm_source=post-email-title&publication_id=676930&post_id=216839751&utm_campaign=email-post-title&isFreemail=true&r=24pqe&triedRedirect=true&utm_medium=email https://sashalatypova.substack.com/p/tucker-carlson-and-150-signatories?utm_source=post-email-title&publication_id=870364&post_id=215763055&utm_campaign=email-post-title&isFreemail=true&r=24pqe&triedRedirect=true&utm_medium=email https://x.com/bloombergtv/status/2102021994346618954?s=43%22%3Ehttps://x.com/bloombergtv/status/2102021994346618954?s=43%3C/a https://x.com/greg_scott84/status/2102443578928894042?s=43%22%3Ehttps://x.com/greg_scott84/status/2102443578928894042?s=43%3C/a https://x.com/jimcsek/status/2098900675321315547?s=43%22%3Ehttps://x.com/jimcsek/status/2098900675321315547?s=43%3C/a https://x.com/ingrahamangle/status/2102198718321611182?s=43%22%3Ehttps://x.com/ingrahamangle/status/2102198718321611182?s=43%3C/a https://x.com/owenbenjamin/status/2101992979330429427?s=43%22%3Ehttps://x.com/owenbenjamin/status/2101992979330429427?s=43%3C/a https://x.com/nickfondacaro/status/2102419698432254083?s=43%22%3Ehttps://x.com/nickfondacaro/status/2102419698432254083?s=43%3C/a https://x.com/stealthqe4/status/2099292146423501291?s=43%22%3Ehttps://x.com/stealthqe4/status/2099292146423501291?s=43%3C/a https://x.com/sfliberty/status/2099547563917451696?s=43%22%3Ehttps://x.com/sfliberty/status/2099547563917451696?s=43%3C/a https://x.com/thedefiantghost/status/2102575678042604030?s=43%22%3Ehttps://x.com/thedefiantghost/status/2102575678042604030?s=43%3C/a https://t.me/grimerica/41540 https://x.com/olooneyjohn/status/2101596628595482963?s=43%22%3Ehttps://x.com/olooneyjohn/status/2101596628595482963?s=43%3C/a https://x.com/childrenshd/status/1653456570414448673?s=43%22%3Ehttps://x.com/childrenshd/status/1653456570414448673?s=43%3C/a       Timestamps (0:00) Early morning roundup and why Graham is in the fields (0:35) Harvest work, combines, and why listeners on machinery matter (1:36) Too hot to hunt and the cost of late-summer weather (2:38) Diesel prices, natural gas costs, and export worries (4:21) Why energy pricing feels artificially managed (6:43) Canada's diesel exposure and regional shortage concerns (12:04) Pierre Poilievre, Carney, and political theater (18:19) MAID clip, medical delays, and the treatment window problem (19:25) Women's peace group clip and the carbon language angle (24:40) "Illusory truth" and Carney's repeated messaging (27:09) Toronto school board and toxic masculinity language (29:27) Trump on immigration and Canadian decline (33:25) Ashton Forbes, anutronic fusion, and future energy theories (44:01) A Los Angeles bridge project as an example of waste (46:55) Hannah Arendt on propaganda and belief collapse (47:17) Ayn Rand on corruption, production, and social decay (58:04) Kibbutz memories, military helicopters, and the Golan Heights (61:15) Slavery compensation, the West India loan, and Rothschild financing (78:41) McCullough study discussion and vaccine-linked illness claims (80:24) RFK Jr., Trump, the PREP Act, and mRNA distrust (83:01) Pentagon talk about battles around the moon and cislunar space

AlabamaCongressman Aderholt announces federal funds to assist in rural healthcare initiativehttps://1819news.com/news/item/makes-all-the-difference-in-the-world-aderholt-dr.-oz-tout-efforts-to-improve-rural-healthcare-drug-pricesSen. Tuberville talks about lowering taxes in state as he runs for governorhttps://1819news.com/news/item/we-all-pay-too-many-taxes-tuberville-reiterates-intention-to-cut-taxes-statewide-while-bringing-in-revenue-in-other-waysCircuit court judge rules in favor of Fenn Church of Calera in his battle against  land grab by Alabama Powerhttps://1819news.com/news/item/arbitrary-and-capricious-judge-rules-in-favor-of-fenn-churchs-property-rights-grants-tpo-in-alabama-power-caseGOP candidate in District 2 state senate race calls on his Democrat opponent to explain accusations of stalking in civil casehttps://1819news.com/news/item/people-of-district-2-deserve-an-explanation-sd-2-gop-nominee-john-roberts-calls-out-democrat-opponent-rudolph-drake-after-stalking-injunction-reportTwo doctors with ties to AL sign onto letter sent to HHS secretary calling for the withdrawal of mRNA vaccines from the markethttps://1819news.com/news/item/alabama-linked-doctors-join-maha-letter-warning-trump-and-rfk-jr-to-ban-mrna-shots-or-lose-supportTwo AL singers are snatched up by Riley Green to be coached on NBC's "The Voice"https://1819news.com/news/item/alabama-talents-steal-show-on-the-voice-season-30-premiereNationalTrump engages with various leaders while at UN over war in Iran and between Ukraine and RussiaVP Vance announces the removal of 500K people on Obamacare as part of anti-fraud task forceFBI experienced a massive cyber hack that affects info on all agents working thereRetired Army flight surgeon, Theresa Long, is part of lawsuit against the Covid 19 vaccine mandate for US military membersDr. Nicholas Hulscher says research on turbo cancers finds direct connections to Pfizer mRNA shot

Day Break | Trump's Message to the World—and the Fight at Home --- 00:00 - Monologue 19:11 – Jonathan Butcher, Acting Director of the Center for Education Policy at The Heritage Foundation. Butcher discusses Heritage's 2026 Education Freedom Report Card, which placed Florida first overall for the fifth consecutive year. He explains the report's criteria—including school choice, teacher freedom, academic transparency, return on education spending, and civics education—and what Heritage believes other states can learn from Florida's approach. 27:57 – Dr. Peter A. McCullough, Chief Scientific Officer at The Wellness Company. Dr. McCullough discusses renewed debate over COVID-19 vaccine safety following an opinion piece calling for additional investigation and scrutiny. He also addresses mRNA technology for influenza vaccines, questions about clinical testing in older adults, traditional flu vaccination, and approaches to staying healthy during flu season. Visit TWC.health/GRUBER and use promo code GRUBER to save 10%. 38:05 - Monologue Featuring Ivey Gruber 47:06 – Angela Stanton King, conservative and pro-life advocate and founder of Auntie Angie's House, which supports pregnant women in crisis. Stanton King discusses the controversy surrounding a holdout juror and the public reaction that followed. She also discusses Black voters, shifting political attitudes, and the issues she believes are influencing Black Americans heading into the elections. 57:20 – Nasser Sharif, founder and President of the California Society for Democracy in Iran. Sharif discusses demonstrations in New York coinciding with an appearance by Iran's president and provides his perspective on the current political situation inside Iran. He also examines the war, opposition to the Iranian government, and competing visions for the country's future. 1:06:20 – Adam Brandon, Senior Advisor to the Independent Center, co-founder of the Independent Leadership Council, and author of The Exhausted Majority: Building a Home for the Politically Homeless. Brandon discusses independent voters and their potential importance in closely contested 2026 midterm races. He examines political dissatisfaction, voters who feel disconnected from both major parties, and the issues motivating independents this election cycle. 1:16:15 - Monologue 1:25:08 – Ron Rademacher, travel writer, author, speaker, storyteller, and host of Around Michigan. Rademacher highlights events, festivals, attractions, and unique destinations happening across Michigan, helping listeners find their next adventure around the state. 1:35:16 – Dr. Ernst Roets, Executive Director of Lex Libertas. Roets discusses a planned display of 3,000 named white crosses in Washington, D.C., intended by organizers to represent victims of farm murders in South Africa. He also discusses South Africa's political landscape, crime, land policy, and the international debate surrounding conditions facing the country's farming communities. 1:44:11 – Ivey Gruber, President of the Michigan Talk Network and co-host of Day Break. Gruber joins Steve to discuss the scale of fraud affecting government programs and recent federal enforcement efforts targeting fraudulent claims and payments. The Government Accountability Office has estimated that federal programs lose roughly $233 billion to $521 billion annually to fraud, while recent Justice Department operations have targeted healthcare, pandemic-relief, and other schemes involving billions of dollars in alleged losses. --- Check out our podcast, 'Forgotten America'... Episode 24 is live NOW at Steve Gruber on YouTube! Link below: https://youtu.be/UrGZQdE62jA

Jason and Jeff pull back the curtain on their Savvy Trader portfolio to examine the core mechanics of long-term portfolio construction. Using real-world examples from their own holdings, the hosts debate the discipline required to let a multi-bagger winner run versus the psychological battle of confronting a 70% drawdown. They tackle the dangerous allure of the sunk-cost fallacy, evaluate whether high-growth portfolios actually benefit from defensive "ballast" stocks, and break down how position sizing can keep single-stock blowups from derailing your long-term compounding.   00:27 Football and Fandom 02:04 College Football Detour 02:44 Back to Investing Talk 03:15 Savvy Trader Concept 06:39 How the Portfolio Works 10:06 Biggest Winner CrowdStrike 14:24 Why Hold CrowdStrike 20:02 Risks and Disruption Fears 23:56 Pivot to Biggest Loser 24:54 Position Size Breakdown 25:39 Lessons From Conviction 29:51 Why Keep Holding 32:29 Sunk Cost And Catalysts 37:24 Guidance Trend Reality Check 38:57 New Stock Ideas Debate 40:04 Ballast Stocks Or Index 45:58 AI Picks And Shovels 50:30 Final Picks And Wrap Up Companies mentioned: AAPL, AMZN, BRK.B, CRWD, FPS, FTNT, GOOG, GOOGL, MELI, MRNA, MRVL, PANW, TJX, TTD, TXN, VOO, ZS   Find where to listen & subscribe,  portfolio contests, and contact information at https://investingunscripted.com ***************************************** To get 15% off any paid plan at fiscal.ai, visit https://fiscal.ai/unscripted ***************************************** Join our Patreon Subscribe to our portfolio on Savvy Trader. Use code Unscripted2026 for 30% off a one-year subscription! Learn more about your ad choices. Visit megaphone.fm/adchoices

SafeBlood is calling attention to two newly published peer-reviewed studies on potential transfusion related risks in the post-mRNA vaccine era, published in the International Journal of Innovative Research in Medical Science. Research was led by maternal-fetal medicine specialist Dr. James A. Thorp, MD, with Dr. R. Clinton Ohlers, PhD — Executive Director, The SafeBlood Foundation — as co-author. Study One: Nine Clinical Cases — Examines nine unvaccinated patients who suffered serious complications post-transfusion, including thromboembolic disease, cardiac inflammation, multi-organ failure, and death; findings are hypothesis-generating, not proof of causation. Study Two: VAERS Signal Analysis — Identifies unusually large reporting signals in federal VAERS data involving thrombotic events, hemorrhage, transfusion complications, and neurological conditions, calling for expanded research and transparency. "These studies are not the end of the scientific conversation — they are the reason the conversation must finally begin." — Dr. R. Clinton Ohlers, PhDSafeblood.comhttps://safeblood.substack.com/?utm_source=global-search

It took FOIA lawsuits and years of hassle for The Federalist to get its hands on 70 Biden admin photos that tell the story of biased justice. Listen to how the FBI under Biden handled Biden's classified documents debacle... and compare that to how the FBI treated Trump and his alleged classified documents scandal. Nic Hulscher and more than 150 scientists demand that Trump and RFK Jr officially remove the mRNA shots from the American healthcare system.    

The FDA’s own trial data should have set off alarm bells. In Moderna’s mRNA flu program, researchers found 23 unexplained deaths in the mRNA group versus nine with conventional flu shots. Disabling Grade 3 reactions hit 5.5 percent versus just 0.9 percent with the comparator. That is not a rounding error. That is a safety signal. A new peer-reviewed reanalysis says the risk-benefit equation is badly upside down. The FDA says the deaths were not proven to be caused by the vaccine. Fine. Then explain the imbalance. Investigate it. Don’t wave it away. Today on Stinchfield: why I believe this mRNA flu shot should be pulled from the market, why the entire mRNA vaccine platform deserves a full safety reckoning, and why Americans should demand answers before regulators ask them to roll up their sleeves again. And if you don’t want the flu shot, that doesn’t mean you have to go into flu season empty-handed. The Wellness Company can help you prepare before you get sick. Their physician-reviewed Contagion Emergency Kit includes prescription medications such as oseltamivir, the generic form of Tamiflu used to treat influenza, along with other medications selected for respiratory illness preparedness. Go to TWC.Health/Grant and use promo code GRANT for 10% off. Don’t wait until the flu hits. Be prepared before it does. See omnystudio.com/listener for privacy information.

AlabamaSen. Tuberville to offer bill that limits # of foreign athletes on college teamshttps://1819news.com/news/item/universities-should-be-prioritizing-american-students-tuberville-bill-would-place-foreign-player-cap-on-college-sports-teamsFederal judge in S. AL puts stay on warrantless searches by ICE agentshttps://1819news.com/news/item/chief-u-s-district-judge-of-southern-alabama-jeffrey-beaverstock-temporarily-blocks-warrantless-immigration-raids-by-dhsHuntsville City Council president slams her Democratic Socialist opponenthttps://1819news.com/news/item/backed-by-democratic-socialists-huntsville-city-council-president-slams-liberal-challenger-ahead-of-tuesday-runoff-electionThe AL Board of Nursing continues with paper applications after cyber attackA member of Perry County Democrat Party attached outside of courthousehttps://1819news.com/news/item/lamont-walker-arrested-after-alleged-assault-outside-perry-county-democrat-executive-committee-meetingA former officer with Montgomery PD convicted of deprivation of rights under color of law involving woman arrested for shopliftinghttps://1819news.com/news/item/former-montgomery-police-officer-convicted-of-depriving-woman-of-civil-rights-obstructing-federal-investigationNationalPresident Trump bans CNN and 2 other media outlets from WH tv pool, mainstream media counters with refusal to cover WH at all on tvGOP House members continue to investigate ActBlue fundraising platformAn anti-ICE fund in MN is quietly dissolved after continuous fraudulent claims for financial reliefThe Data Center Watch group says 45 data centers delayed after grassroots uprisingLetter sent to HHS Secretary regarding his failure to truly be MAHA by removing mRNA vaccines from the marketEpidemiologist says vaccines given to kids contains the necessary pathogens for creating the AlphaGal syndrome normally associated with tick bites

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about the injury to Caleb Williams, if there is any difference between name-brand medicine or the generic version, the types of vaccines that are available right now, why he believes everyone should get a COVID vaccine, and […]

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about the injury to Caleb Williams, if there is any difference between name-brand medicine or the generic version, the types of vaccines that are available right now, why he believes everyone should get a COVID vaccine, and […]

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about the injury to Caleb Williams, if there is any difference between name-brand medicine or the generic version, the types of vaccines that are available right now, why he believes everyone should get a COVID vaccine, and […]

In this episode of John Solomon Reports, host John Solomon dives deep into the pressing issues facing America today, including the weaponization of government, election integrity, and the growing threat from China. Broadcasting live from the newly named JTN Marketplace studios in Washington, D.C., Solomon shares exciting updates about the Just the News official store, featuring products like the newly launched Just the Brew coffee and exclusive books that support investigative journalism.Joining the show is Congressman Josh Brecheen from Oklahoma, who discusses the urgent need to address the national debt and the challenges Congress faces in making meaningful progress. Brecheen sheds light on the over 600 pieces of legislation stalled in the Senate, emphasizing the need for action.In the second interview, Solomon covers the high-stakes foreign summit happening in Washington, D.C., where President Trump will meet with President Xi of China. Fred Fleitz, former chief of staff to the National Security Council, joins to analyze the implications of this meeting, touching on critical topics such as AI, sanctions, and China's economic challenges.The episode also addresses the recent controversy surrounding media access to the White House, with CNN and other outlets facing bans due to alleged inaccuracies. Media Research Center's Tim Graham provides insights into the evolving landscape of media coverage and the implications for transparency.Finally, Dr. Chad Walding, from our great partners NativePath, returns for the weekly health news update, discussing the importance of hydration and why simply drinking water may not be enough as we age. Solomon highlights the growing concerns about mRNA vaccines, featuring a letter from notable health freedom advocates expressing their frustrations with the current administration's stance on vaccination.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome to The Daily Wrap Up, an in-depth investigatory show dedicated to bringing you the most relevant independent news, as we see it, from the last 24 hours (9/20/26). As always, take the information discussed in the video below and research it for yourself, and come to your own conclusions. Anyone telling you what the truth is, or claiming they have the answer, is likely leading you astray, for one reason or another. Stay Vigilant. !function(r,u,m,b,l,e){r._Rumble=b,r[b]||(r[b]=function(){(r[b]._=r[b]._||[]).push(arguments);if(r[b]._.length==1){l=u.createElement(m),e=u.getElementsByTagName(m)[0],l.async=1,l.src="https://rumble.com/embedJS/u2q643"+(arguments[1].video?'.'+arguments[1].video:'')+"/?url="+encodeURIComponent(location.href)+"&args="+encodeURIComponent(JSON.stringify([].slice.apply(arguments))),e.parentNode.insertBefore(l,e)}})}(window, document, "script", "Rumble");   Rumble("play", {"video":"v7dl27k","div":"rumble_v7dl27k"}); Source Links (In Chronological Order): (8) The Last American Vagabond on X: "And I guess they think "healthy" is more deadly mRNA shots, more PFAS, more glyphosate, more pesticides, etc., etc., etc. They either don't think we are smart enough to see it, or they don't know what else to do but lie." / X (8) UNSHADOWED (formerly IceAgeFarmer) on X: "Diesel Is the Pretext... Diesel is at record highs. The IEA, WEF, and FAO already published the response to this crisis: fuel rationing, plate-based road limits, farm AI, water caps, then Digital ID. As folks start to cry out, and the political willpower is manufactured," / X (8) UNSHADOWED (formerly IceAgeFarmer) on X: "Event 201 for Food? In 2015, John Podesta's Center for American Progress co-hosted a tabletop exercise with WWF, Cargill, Mars, and CNA: Food Chain Reaction: A Global Food Security Game. The event "imagined" a food crisis brought about by geopolitical instability and climate https://t.co/Tgswwth2Ok" / X New Tab IS MILITARY RESEARCH HAZARDOUS TO VETERANS' HEALTH? Compulsory moral bioenhancement should be covert - PubMed Operation Sea-Spray - Wikipedia 'Expose Warp Speed' With Whitney Webb, Chips Gels And Sensors On The Way & The Trump COVID Psyop The Eugenicist Mindset Propelling Operation Warp Speed w/ Whitney Webb Israel Uses Bibas Kids (Killed By IDF) To Violate Ceasefire & Stargate Is Operation Warp Speed 2.0 US Army Has Admitted To Conducting 100s Of Germ Warfare Tests On Americans In Coronavirus We Trust: Medical Surveillance State For A Gov That's Experimented On You 239 Times (8) Jessica Rojas